Carbonic	carbonic	JJ	O
anhydrases	anhydrase	NNS	O
are	be	VBP	O
metalloenzymes	metalloenzymes	NNP	O
,	,	,	O
present	present	JJ	O
in	in	IN	O
most	most	JJS	O
of	of	IN	O
the	the	DT	O
living	live	VBG	O
organisms	organism	NNS	O
and	and	CC	O
encoded	encode	VBN	O
by	by	IN	O
seven	seven	CD	O
evolutionarily	evolutionarily	RB	O
unrelated	unrelated	JJ	O
gene	gene	NN	O
families	family	NNS	O
:	:	:	O
the	the	DT	O
Î±-	Î±-	NNP	O
.	.	.	O

Î²-	î²-	UH	O
.	.	.	O

Î³-	î³-	UH	O
.	.	.	O

Î´-	Î´-	NNP	O
.	.	.	O

Î¶-	î¶-	ADD	O
.	.	.	O

Î·-	î·-	ADD	O
.	.	.	O

and	and	CC	O
Î¸-CAs	î¸-cas	CD	B
.	.	.	O

The	the	DT	O
CAs	CAs	NNP	O
catalyse	catalyse	VBP	O
the	the	DT	O
basic	basic	JJ	O
reaction	reaction	NN	O
of	of	IN	O
reversible	reversible	JJ	O
hydration	hydration	NN	O
of	of	IN	O
carbon	carbon	NN	O
dioxide	dioxide	NN	O
to	to	TO	O
bicarbonate	bicarbonate	VB	O
and	and	CC	O
proton	proton	JJ	B
.	.	.	O

This	this	DT	O
reaction	reaction	NN	O
is	be	VBZ	O
fundamental	fundamental	JJ	O
for	for	IN	O
biochemical	biochemical	JJ	O
processes	process	NNS	O
in	in	IN	O
all	all	DT	O
living	live	VBG	O
organisms	organism	NNS	B
,	,	,	B
.	.	.	O

Invertebrates	Invertebrates	NNPS	O
and	and	CC	O
lower	low	JJR	O
organisms	organism	NNS	O
contain	contain	VBP	O
all	all	PDT	O
the	the	DT	O
seven	seven	CD	O
members	member	NNS	O
of	of	IN	O
CA	CA	NNP	O
gene	gene	NN	O
families	family	NNS	O
and	and	CC	O
,	,	,	O
in	in	IN	O
some	some	DT	O
cases	case	NNS	O
,	,	,	O
multiple	multiple	JJ	O
gene	gene	NN	O
families	family	NNS	O
with	with	IN	O
in	in	IN	O
the	the	DT	O
same	same	JJ	O
organism	organism	NN	B
.	.	.	O

In	in	IN	O
contrast	contrast	NN	O
,	,	,	O
vertebrates	vertebrate	NNS	O
and	and	CC	O
mammals	mammal	NNS	O
contain	contain	VBP	O
only	only	RB	O
Î±-CAs	î±-cas	JJ	B
.	.	.	O

In	in	IN	O
humans	human	NNS	O
,	,	,	O
the	the	DT	O
CAs	ca	NNS	O
regulate	regulate	VBP	O
a	a	DT	O
broad	broad	JJ	O
range	range	NN	O
of	of	IN	O
physiological	physiological	JJ	O
processes	process	NNS	O
,	,	,	O
such	such	JJ	O
as	as	IN	O
respiration	respiration	NN	O
,	,	,	O
transport	transport	NN	O
of	of	IN	O
carbon	carbon	NN	O
dioxide	dioxide	NN	O
/	/	SYM	O
bicarbonate	bicarbonate	NN	O
between	between	IN	O
the	the	DT	O
lung	lung	NN	O
and	and	CC	O
metabolising	metabolise	VBG	O
tissues	tissue	NNS	O
,	,	,	O
pH	pH	NNP	O
homeostasis	homeostasis	NN	O
,	,	,	O
and	and	CC	O
electrolyte	electrolyte	NNP	O
secretion	secretion	NN	O
in	in	IN	O
many	many	JJ	O
tissues	tissue	NNS	O
and	and	CC	O
organs	organ	NNS	B
.	.	.	O

There	there	EX	O
are	be	VBP	O
15	15	CD	O
CA	CA	NNP	O
isoforms	isoform	NNS	O
in	in	IN	O
humans	human	NNS	O
of	of	IN	O
which	which	WDT	O
12	12	CD	O
are	be	VBP	O
catalytically	catalytically	RB	O
active	active	JJ	O
.	.	.	O

Three	three	CD	O
are	be	VBP	O
inactive	inactive	JJ	O
due	due	IN	O
to	to	IN	O
the	the	DT	O
lack	lack	NN	O
of	of	IN	O
one	one	CD	O
or	or	CC	O
more	more	JJR	O
of	of	IN	O
the	the	DT	O
three	three	CD	O
-	-	HYPH	O
histidine	histidine	NN	O
residues	residue	NNS	O
required	require	VBN	O
for	for	IN	O
enzymatic	enzymatic	JJ	O
activity	activity	NN	B
.	.	.	O

The	the	DT	O
human	human	JJ	O
CA	CA	NNP	O
isoforms	isoform	NNS	O
differ	differ	VBP	O
from	from	IN	O
one	one	CD	O
another	another	DT	O
in	in	IN	O
cellular	cellular	JJ	O
localisation	localisation	NN	O
,	,	,	O
distribution	distribution	NN	O
in	in	IN	O
organs	organ	NNS	O
,	,	,	O
levels	level	NNS	O
of	of	IN	O
expression	expression	NN	O
in	in	IN	O
tissues	tissue	NNS	O
and	and	CC	O
their	-PRON-	PRP$	O
kinetic	kinetic	JJ	O
properties	property	NNS	B
.	.	.	O

The	the	DT	O
human	human	JJ	O
CA	CA	NNP	O
isoforms	isoform	NNS	O
have	have	VBP	O
high	high	JJ	O
sequence	sequence	NN	O
and	and	CC	O
structural	structural	JJ	O
similarities	similarity	NNS	O
,	,	,	O
and	and	CC	O
therefore	therefore	RB	O
only	only	RB	O
subtle	subtle	JJ	O
differences	difference	NNS	O
exist	exist	VBP	O
in	in	IN	O
their	-PRON-	PRP$	O
active	active	JJ	O
sites	site	NNS	B
.	.	.	O

In	in	IN	O
humans	human	NNS	O
,	,	,	O
increased	increase	VBN	O
expression	expression	NN	O
of	of	IN	O
CA	CA	NNP	O
isoforms	isoform	NNS	O
is	be	VBZ	O
sometimes	sometimes	RB	O
associated	associate	VBN	O
with	with	IN	O
certain	certain	JJ	O
disease	disease	NN	O
conditions	condition	NNS	B
.	.	.	O

The	the	DT	O
cytosolic	cytosolic	NN	O
hCA	hca	NN	O
I	-PRON-	PRP	O
and	and	CC	O
II	II	NNP	O
proteins	protein	NNS	O
have	have	VBP	O
been	be	VBN	O
linked	link	VBN	O
to	to	IN	O
retinal	retinal	JJ	O
and	and	CC	O
cerebral	cerebral	JJ	O
oedema	oedema	NNP	O
,	,	,	O
glaucoma	glaucoma	NN	O
,	,	,	O
epilepsy	epilepsy	NN	O
and	and	CC	O
altitude	altitude	VB	O
sickness	sickness	NN	B
,	,	,	B
.	.	.	O

hCA	hCA	NNP	O
IX	IX	NNP	O
,	,	,	O
a	a	DT	O
transmembrane	transmembrane	JJ	O
CA	CA	NNP	O
isoform	isoform	NN	O
,	,	,	O
is	be	VBZ	O
overexpressed	overexpresse	VBN	O
under	under	IN	O
hypoxic	hypoxic	JJ	O
conditions	condition	NNS	O
in	in	IN	O
solid	solid	JJ	O
tumours	tumour	NNS	O
and	and	CC	O
is	be	VBZ	O
involved	involve	VBN	O
in	in	IN	O
the	the	DT	O
progression	progression	NN	O
of	of	IN	O
cancer	cancer	NN	B
,	,	,	B
.	.	.	O

Many	many	JJ	O
CA	CA	NNP	O
inhibitors	inhibitor	NNS	O
have	have	VBP	O
been	be	VBN	O
used	use	VBN	O
for	for	IN	O
treating	treat	VBG	O
various	various	JJ	O
human	human	JJ	O
diseases	disease	NNS	B
.	.	.	O

Even	even	RB	O
if	if	IN	O
the	the	DT	O
inhibitors	inhibitor	NNS	O
achieve	achieve	VBP	O
desirable	desirable	JJ	O
therapeutic	therapeutic	JJ	O
effects	effect	NNS	O
,	,	,	O
they	-PRON-	PRP	O
may	may	MD	O
cause	cause	VB	O
unacceptable	unacceptable	JJ	O
level	level	NN	O
of	of	IN	O
toxicity	toxicity	NN	O
in	in	IN	O
humans	human	NNS	B
,	,	,	B
,	,	,	O
most	most	RBS	O
probably	probably	RB	O
due	due	IN	O
to	to	IN	O
the	the	DT	O
off	off	JJ	O
-	-	HYPH	O
target	target	NN	O
effects	effect	NNS	O
attributable	attributable	JJ	O
to	to	IN	O
the	the	DT	O
inhibition	inhibition	NN	O
of	of	IN	O
CA	CA	NNP	O
isoforms	isoform	NNS	O
that	that	WDT	O
are	be	VBP	O
not	not	RB	O
involved	involve	VBN	O
in	in	IN	O
the	the	DT	O
target	target	NN	O
disease	disease	NN	O
or	or	CC	O
due	due	IN	O
to	to	IN	O
general	general	JJ	O
toxic	toxic	JJ	O
effects	effect	NNS	O
of	of	IN	O
the	the	DT	O
chemical	chemical	NN	B
,	,	,	B
.	.	.	O

Therefore	therefore	RB	O
,	,	,	O
to	to	TO	O
target	target	VB	O
particular	particular	JJ	O
therapeutic	therapeutic	JJ	O
areas	area	NNS	O
with	with	IN	O
minimal	minimal	JJ	O
off	off	JJ	O
-	-	HYPH	O
target	target	NN	O
effects	effect	NNS	O
,	,	,	O
inhibition	inhibition	NN	O
of	of	IN	O
specific	specific	JJ	O
enzymes	enzyme	NNS	O
is	be	VBZ	O
necessary	necessary	JJ	O
.	.	.	O

Thus	thus	RB	O
,	,	,	O
there	there	EX	O
is	be	VBZ	O
a	a	DT	O
particular	particular	JJ	O
need	need	NN	O
to	to	TO	O
develop	develop	VB	O
inhibitors	inhibitor	NNS	O
that	that	WDT	O
are	be	VBP	O
not	not	RB	O
only	only	RB	O
selective	selective	JJ	O
against	against	IN	O
the	the	DT	O
human	human	JJ	O
CAs	ca	NNS	O
but	but	CC	O
are	be	VBP	O
also	also	RB	O
safe	safe	JJ	O
for	for	IN	O
clinical	clinical	JJ	O
use	use	NN	B
.	.	.	O

Along	along	IN	O
this	this	DT	O
line	line	NN	O
,	,	,	O
we	-PRON-	PRP	O
have	have	VBP	O
previously	previously	RB	O
developed	develop	VBN	O
numerous	numerous	JJ	O
potent	potent	JJ	O
CA	CA	NNP	O
inhibitors	inhibitor	NNS	O
that	that	WDT	O
are	be	VBP	O
not	not	RB	O
only	only	RB	O
effective	effective	JJ	O
against	against	IN	O
specific	specific	JJ	O
human	human	NN	O
Î±-CAs	î±-cas	JJ	O
and	and	CC	O
mycobacterial	mycobacterial	NNP	O
Î²-CAs	Î²-CAs	NNP	O
,	,	,	O
but	but	CC	O
also	also	RB	O
show	show	VBP	O
minimal	minimal	JJ	O
toxicity	toxicity	NN	O
and	and	CC	O
are	be	VBP	O
suitable	suitable	JJ	O
for	for	IN	O
developing	develop	VBG	O
further	far	RBR	O
for	for	IN	O
clinical	clinical	JJ	O
use	use	NN	O
as	as	IN	O
drugs	drug	NNS	B
.	.	.	O

Recently	recently	RB	O
,	,	,	O
we	-PRON-	PRP	O
reported	report	VBD	O
sulphonamide	sulphonamide	NN	O
and	and	CC	O
carbamate	carbamate	NN	O
compounds	compound	NNS	O
as	as	IN	O
hCA	hca	CD	O
IX	IX	NNP	O
and	and	CC	O
mycobacterial	mycobacterial	NN	O
Î²-CA	Î²-CA	-LRB-	O
inhibitors	inhibitor	NNS	B
.	.	.	O

In	in	IN	O
addition	addition	NN	O
to	to	IN	O
the	the	DT	O
synthesis	synthesis	NN	O
and	and	CC	O
inÂ	inÂ	NNP	O
vitro	vitro	FW	O
and	and	CC	O
inÂ	inÂ	NNP	O
vivo	vivo	NN	O
evaluation	evaluation	NN	O
of	of	IN	O
these	these	DT	O
compounds	compound	NNS	O
,	,	,	O
we	-PRON-	PRP	O
also	also	RB	O
tested	test	VBD	O
them	-PRON-	PRP	O
for	for	IN	O
safety	safety	NN	O
and	and	CC	O
toxicity	toxicity	NN	O
using	use	VBG	O
1â5âd	1â5âd	CD	O
post	post	JJ	O
-	-	JJ	O
fertilisation	fertilisation	JJ	O
zebrafish	zebrafish	JJ	O
larvae	larvae	NN	O
.	.	.	O

Our	-PRON-	PRP$	O
studies	study	NNS	O
showed	show	VBD	O
that	that	IN	O
these	these	DT	O
inhibitors	inhibitor	NNS	O
are	be	VBP	O
safe	safe	JJ	O
for	for	IN	O
further	further	JJ	O
preclinical	preclinical	JJ	O
characterisation	characterisation	NN	O
using	use	VBG	O
inÂ	inÂ	NNP	O
vivo	vivo	NN	O
models	model	NNS	B
.	.	.	O

In	in	IN	O
addition	addition	NN	O
,	,	,	O
in	in	IN	O
this	this	DT	O
study	study	NN	O
,	,	,	O
we	-PRON-	PRP	O
were	be	VBD	O
interested	interested	JJ	O
in	in	IN	O
incorporating	incorporate	VBG	O
a	a	DT	O
nitro	nitro	NNP	O
-	-	HYPH	O
imidazole	imidazole	NN	O
moiety	moiety	NN	O
as	as	IN	O
a	a	DT	O
privileged	privileged	JJ	O
hypoxia	hypoxia	NN	O
sensitising	sensitising	NN	O
scaffold	scaffold	JJ	O
in	in	IN	O
the	the	DT	O
structure	structure	NN	O
of	of	IN	O
CA	CA	NNP	O
inhibitors	inhibitor	NNS	O
.	.	.	O

The	the	DT	O
rationale	rationale	NN	O
was	be	VBD	O
to	to	TO	O
investigate	investigate	VB	O
a	a	DT	O
strategy	strategy	NN	O
of	of	IN	O
dual	dual	JJ	O
targeting	targeting	NN	O
in	in	IN	O
the	the	DT	O
context	context	NN	O
of	of	IN	O
anticancer	anticancer	NN	O
agents	agent	NNS	B
.	.	.	O

Previous	previous	JJ	O
results	result	NNS	O
have	have	VBP	O
shown	show	VBN	O
the	the	DT	O
validity	validity	NN	O
of	of	IN	O
this	this	DT	O
approach	approach	NN	O
when	when	WRB	O
conjugation	conjugation	NN	O
of	of	IN	O
5-nitroimidazole	5-nitroimidazole	CD	O
derivatives	derivative	NNS	O
to	to	IN	O
CA	CA	NNP	O
inhibitors	inhibitor	NNS	O
structures	structure	NNS	O
led	lead	VBD	O
to	to	IN	O
new	new	JJ	O
radiosensitiser	radiosensitiser	NN	O
agents	agent	NNS	O
targeting	target	VBG	O
hypoxic	hypoxic	RB	O
tumours	tumour	VBZ	B
.	.	.	O

To	to	TO	O
further	further	RB	O
investigate	investigate	VB	O
the	the	DT	O
effect	effect	NN	O
and	and	CC	O
the	the	DT	O
influence	influence	NN	O
of	of	IN	O
the	the	DT	O
5-nitro	5-nitro	CD	O
imidazole	imidazole	NN	O
moiety	moiety	NN	O
and	and	CC	O
develop	develop	VB	O
new	new	JJ	O
potent	potent	JJ	O
and	and	CC	O
safer	safe	JJR	O
inhibitors	inhibitor	NNS	O
,	,	,	O
we	-PRON-	PRP	O
have	have	VBP	O
been	be	VBN	O
continuing	continue	VBG	O
our	-PRON-	PRP$	O
research	research	NN	O
on	on	IN	O
new	new	JJ	O
inhibitors	inhibitor	NNS	O
in	in	IN	O
the	the	DT	O
nitroimidazole	nitroimidazole	NN	O
series	series	NN	O
.	.	.	O

In	in	IN	O
the	the	DT	O
present	present	JJ	O
study	study	NN	O
,	,	,	O
we	-PRON-	PRP	O
report	report	VBP	O
the	the	DT	O
design	design	NN	O
,	,	,	O
synthesis	synthesis	NN	O
,	,	,	O
inÂ	inÂ	NNP	O
vitro	vitro	FW	O
CA	CA	NNP	O
inhibition	inhibition	NN	O
,	,	,	O
and	and	CC	O
evaluation	evaluation	NN	O
of	of	IN	O
toxicity	toxicity	NN	O
of	of	IN	O
novel	novel	NN	O
thiourea	thiourea	NNP	O
derivatives	derivative	VBZ	O
3	3	CD	O
and	and	CC	O
4	4	CD	O
and	and	CC	O
a	a	DT	O
sulphonamide	sulphonamide	NN	O
derivative	derivative	JJ	O
10	10	CD	O
using	use	VBG	O
zebrafish	zebrafish	JJ	O
larvae	larvae	NN	O
.	.	.	O

All	all	DT	O
reagents	reagent	NNS	O
and	and	CC	O
solvents	solvent	NNS	O
were	be	VBD	O
of	of	IN	O
commercial	commercial	JJ	O
quality	quality	NN	O
and	and	CC	O
used	use	VBN	O
without	without	IN	O
further	further	JJ	O
purification	purification	NN	O
unless	unless	IN	O
otherwise	otherwise	RB	O
specified	specify	VBN	O
.	.	.	O

All	all	DT	O
reactions	reaction	NNS	O
were	be	VBD	O
carried	carry	VBN	O
out	out	RP	O
under	under	IN	O
an	an	DT	O
inert	inert	JJ	O
atmosphere	atmosphere	NN	O
of	of	IN	O
nitrogen	nitrogen	NN	O
.	.	.	O

TLC	tlc	NN	O
analyses	analysis	NNS	O
were	be	VBD	O
performed	perform	VBN	O
on	on	IN	O
silica	silica	NNP	O
gel	gel	NNP	O
60	60	CD	O
F254	F254	NNP	O
plates	plate	NNS	O
.	.	.	O

Spots	spot	NNS	O
were	be	VBD	O
visualised	visualise	VBN	O
under	under	IN	O
254ânm	254ânm	CD	O
UV	uv	NN	O
illumination	illumination	NN	O
or	or	CC	O
by	by	IN	O
ninhydrin	ninhydrin	NNP	O
solution	solution	NN	O
spraying	spraying	NN	O
.	.	.	O

Melting	melt	VBG	O
points	point	NNS	O
were	be	VBD	O
determined	determine	VBN	O
on	on	IN	O
a	a	DT	O
BÃ¼chi	BÃ¼chi	NNP	O
Melting	melt	VBG	O
Point	Point	NNP	O
510	510	CD	O
and	and	CC	O
are	be	VBP	O
uncorrected	uncorrected	JJ	O
.	.	.	O

1H	1H	NNP	O
and	and	CC	O
13C	13C	NNP	O
NMR	NMR	NNP	O
spectra	spectra	NNP	O
were	be	VBD	O
recorded	record	VBN	O
on	on	IN	O
Bruker	Bruker	NNP	O
DRX-400	DRX-400	NNP	O
spectrometer	spectrometer	VB	O
using	use	VBG	O
DMSO	DMSO	NNP	O
-	-	HYPH	O
d6	d6	NN	O
as	as	IN	O
solvent	solvent	NN	O
and	and	CC	O
tetramethylsilane	tetramethylsilane	NN	O
as	as	IN	O
internal	internal	JJ	O
standard	standard	NN	O
.	.	.	O

For	for	IN	O
1H	1h	JJ	O
NMR	NMR	NNP	O
spectra	spectra	NNP	O
,	,	,	O
chemical	chemical	JJ	O
shifts	shift	NNS	O
are	be	VBP	O
expressed	express	VBN	O
in	in	IN	O
Î	Î	NNP	O
´	´	CD	O
downfield	downfield	NN	O
from	from	IN	O
tetramethylsilane	tetramethylsilane	NN	O
and	and	CC	O
coupling	couple	VBG	O
constants	constant	NNS	O
are	be	VBP	O
expressed	express	VBN	O
in	in	IN	O
Hertz	Hertz	NNP	O
.	.	.	O

Electron	Electron	NNP	O
ionisation	ionisation	NN	O
mass	mass	NN	O
spectra	spectra	NNP	O
were	be	VBD	O
recorded	record	VBN	O
in	in	IN	O
positive	positive	JJ	O
or	or	CC	O
negative	negative	JJ	O
mode	mode	NN	O
on	on	IN	O
a	a	DT	O
Water	Water	NNP	O
MicroMass	MicroMass	NNP	O
ZQ	ZQ	NNP	O
.	.	.	O

All	all	DT	O
compounds	compound	NNS	O
that	that	WDT	O
were	be	VBD	O
tested	test	VBN	O
against	against	IN	O
purified	purify	VBN	O
physiological	physiological	JJ	O
isoforms	isoform	NNS	O
of	of	IN	O
CAs	ca	NNS	O
were	be	VBD	O
analysed	analyse	VBN	O
by	by	IN	O
high	high	JJ	O
-	-	HYPH	O
resolution	resolution	NN	O
ESI	ESI	NNP	O
mass	mass	NN	O
spectra	spectra	NNP	O
using	use	VBG	O
on	on	IN	O
a	a	DT	O
Q	Q	NNP	O
-	-	HYPH	O
ToFI	ToFI	NNP	O
mass	mass	NN	O
spectrometer	spectrometer	NN	O
fitted	fit	VBD	O
with	with	IN	O
an	an	DT	O
electrospray	electrospray	NN	O
ion	ion	NN	O
source	source	NN	O
to	to	TO	O
confirm	confirm	VB	O
the	the	DT	O
purity	purity	NN	O
of	of	IN	O
>	>	XX	O
95%.1	95%.1	CD	O
-	-	HYPH	O
-2-methyl-5-nitro-1H	-2-methyl-5-nitro-1h	NN	O
-	-	HYPH	O
imidazole	imidazole	NN	O
:	:	:	O
Thiophosgene	thiophosgene	JJ	O
and	and	CC	O
sodium	sodium	NN	O
hydroxide	hydroxide	NN	O
were	be	VBD	O
added	add	VBN	O
to	to	IN	O
a	a	DT	O
solution	solution	NN	O
of	of	IN	O
1	1	CD	O
in	in	IN	O
chloroform	chloroform	NN	O
and	and	CC	O
water	water	NN	O
at	at	IN	O
0âÂ	0ââ	CD	O
°	°	NNP	O
C	C	NNP	O
,	,	,	O
and	and	CC	O
reaction	reaction	NN	O
mixture	mixture	NN	O
was	be	VBD	O
warmed	warm	VBN	O
to	to	TO	O
room	room	VB	O
temperature	temperature	NN	O
.	.	.	O

Thin	thin	JJ	O
layer	layer	NN	O
Chromatography	Chromatography	NNP	O
confirmed	confirm	VBD	O
complete	complete	JJ	O
disappearance	disappearance	NN	O
of	of	IN	O
the	the	DT	O
starting	starting	NN	O
material	material	NN	O
.	.	.	O

Reaction	reaction	NN	O
mixture	mixture	NN	O
was	be	VBD	O
then	then	RB	O
washed	wash	VBN	O
with	with	IN	O
water	water	NN	O
and	and	CC	O
extracted	extract	VBN	O
with	with	IN	O
DCM	DCM	NNP	O
.	.	.	O

The	the	DT	O
organic	organic	JJ	O
layer	layer	NN	O
was	be	VBD	O
dried	dry	VBN	O
over	over	IN	O
anhydrous	anhydrous	JJ	O
sodium	sodium	NN	O
sulphate	sulphate	NN	O
,	,	,	O
filtered	filter	VBN	O
and	and	CC	O
evaporated	evaporate	VBD	O
to	to	TO	O
get	get	VB	O
crude	crude	JJ	O
compound	compound	NN	O
which	which	WDT	O
was	be	VBD	O
purified	purify	VBN	O
by	by	IN	O
chromatography	chromatography	NN	O
on	on	IN	O
silica	silica	NNP	O
gel	gel	NNP	O
using	use	VBG	O
ethyl	ethyl	NNP	O
acetate	acetate	NNP	O
and	and	CC	O
petroleum	petroleum	NN	O
ether	ether	NN	O
as	as	IN	O
eluent	eluent	NN	O
with	with	IN	O
a	a	DT	O
gradient	gradient	NN	O
from	from	IN	O
5:5	5:5	CD	O
to	to	IN	O
9:1	9:1	CD	O
.	.	.	O

Yield	yield	NN	O
:	:	:	O
64	64	CD	O
%	%	NN	O
,	,	,	O
1H	1H	NNP	O
NMR	NMR	NNP	O
400âMHz	400âmhz	CD	O
,	,	,	O
DMSO	DMSO	NNP	O
-	-	HYPH	O
d6	d6	NN	O
Î	Î	NNP	O
´	´	CD	O
8.10	8.10	CD	O
,	,	,	O
4.65â4.60	4.65â4.60	CD	O
,	,	,	O
4.17â4.12	4.17â4.12	CD	O
,	,	,	O
3.35	3.35	CD	O
.	.	.	O

13C	13c	CD	O
NMR	NMR	NNP	O
101âMHz	101âmhz	CD	O
,	,	,	O
DMSO	DMSO	NNP	O
-	-	HYPH	O
d6	d6	NN	O
Î	Î	NNP	O
´	´	CD	O
151.80	151.80	CD	O
,	,	,	O
138.80	138.80	CD	O
,	,	,	O
133.65	133.65	CD	O
,	,	,	O
129.62	129.62	CD	O
,	,	,	O
45.06	45.06	CD	O
,	,	,	O
14.28	14.28	CD	O
.	.	.	O

MS	MS	NNP	O
m	m	NNP	O
/	/	SYM	O
z	z	NNP	O
213.04	213.04	CD	O
Mâ+âH]+.4-(2-(3-(2-ethyl)thioureido)ethyl)phenyl	Mâ+âH]+.4-(2-(3-(2-ethyl)thioureido)ethyl)phenyl	NNP	O
sulphamide	sulphamide	NN	O
:	:	:	O
4-aniline	4-aniline	CD	O
was	be	VBD	O
added	add	VBN	O
to	to	IN	O
a	a	DT	O
solution	solution	NN	O
of	of	IN	O
2	2	CD	O
in	in	IN	O
acetonitrile	acetonitrile	NNP	O
and	and	CC	O
allowed	allow	VBN	O
to	to	TO	O
stir	stir	VB	O
at	at	IN	O
room	room	NN	O
temperature	temperature	NN	O
overnight	overnight	RB	O
.	.	.	O

Reaction	reaction	NN	O
mixture	mixture	NN	O
was	be	VBD	O
washed	wash	VBN	O
with	with	IN	O
water	water	NN	O
and	and	CC	O
extracted	extract	VBN	O
with	with	IN	O
ethyl	ethyl	NN	O
acetate	acetate	NN	O
.	.	.	O

The	the	DT	O
organic	organic	JJ	O
layer	layer	NN	O
was	be	VBD	O
dried	dry	VBN	O
over	over	IN	O
anhydrous	anhydrous	JJ	O
sodium	sodium	NN	O
sulphate	sulphate	NN	O
,	,	,	O
filtered	filter	VBN	O
and	and	CC	O
evaporated	evaporate	VBN	O
under	under	IN	O
vacuum	vacuum	NN	O
to	to	TO	O
get	get	VB	O
crude	crude	JJ	O
compound	compound	NN	O
which	which	WDT	O
was	be	VBD	O
then	then	RB	O
reacted	react	VBN	O
as	as	RB	O
-	-	HYPH	O
is	be	VBZ	O
with	with	IN	O
sulphamoyl	sulphamoyl	JJ	O
chloride	chloride	NN	O
in	in	IN	O
dimethylacetamide	dimethylacetamide	NN	O
.	.	.	O

After	after	IN	O
stirring	stir	VBG	O
for	for	IN	O
one	one	CD	O
night	night	NN	O
at	at	IN	O
room	room	NN	O
temperature	temperature	NN	O
,	,	,	O
the	the	DT	O
mixture	mixture	NN	O
was	be	VBD	O
diluted	dilute	VBN	O
with	with	IN	O
ethyl	ethyl	NN	O
acetate	acetate	NNP	O
,	,	,	O
and	and	CC	O
washed	wash	VBD	O
three	three	CD	O
times	time	NNS	O
with	with	IN	O
water	water	NN	O
.	.	.	O

The	the	DT	O
organic	organic	JJ	O
layer	layer	NN	O
was	be	VBD	O
dried	dry	VBN	O
over	over	IN	O
anhydrous	anhydrous	JJ	O
magnesium	magnesium	NN	O
sulphate	sulphate	NN	O
and	and	CC	O
concentrated	concentrate	VBD	O
under	under	IN	O
vacuum	vacuum	NN	O
.	.	.	O

The	the	DT	O
residue	residue	NN	O
was	be	VBD	O
purified	purify	VBN	O
by	by	IN	O
chromatography	chromatography	NN	O
on	on	IN	O
silica	silica	NNP	O
gel	gel	NNP	O
using	use	VBG	O
methylene	methylene	JJ	O
chloride	chloride	NN	O
-	-	HYPH	O
methanol	methanol	NN	O
9:1	9:1	CD	O
as	as	IN	O
eluent	eluent	NN	O
.	.	.	O

Yield	yield	NN	O
:	:	:	O
43	43	CD	O
%	%	NN	O
,	,	,	O
1H	1H	NNP	O
NMR	NMR	NNP	O
400âMHz	400âmhz	CD	O
,	,	,	O
DMSO	DMSO	NNP	O
-	-	HYPH	O
d6	d6	NN	O
Î	Î	NNP	O
´	´	CD	O
9.35	9.35	CD	O
,	,	,	O
8.03	8.03	CD	O
,	,	,	O
7.51	7.51	CD	O
,	,	,	O
7.11	7.11	CD	O
d	d	NNP	O
,	,	,	O
Jâ=â9.1	Jâ=â9.1	NNP	O
,	,	,	O
4H	4H	NNP	O
,	,	,	O
7.01	7.01	CD	O
,	,	,	O
4.41	4.41	CD	O
,	,	,	O
3.81	3.81	CD	O
,	,	,	O
2.68	2.68	CD	O
,	,	,	O
2.36	2.36	CD	O
.	.	.	O

13C	13c	CD	O
NMR	NMR	NNP	O
101âMHz	101âmhz	CD	O
,	,	,	O
DMSO	DMSO	NNP	O
-	-	HYPH	O
d6	d6	NN	O
Î	Î	NNP	O
´	´	CD	O
151.98	151.98	CD	O
,	,	,	O
139.08	139.08	CD	O
,	,	,	O
138.13	138.13	CD	O
,	,	,	O
133.70	133.70	CD	O
,	,	,	O
133.45â133.11	133.45â133.11	CD	O
,	,	,	O
129.40	129.40	CD	O
,	,	,	O
118.95	118.95	CD	O
,	,	,	O
55.38	55.38	CD	O
,	,	,	O
45.93	45.93	CD	O
,	,	,	O
14.30	14.30	CD	O
.	.	.	O

MS	MS	NNP	O
m	m	NNP	O
/	/	SYM	O
z	z	NNP	O
428.12	428.12	CD	O
Mâ+âH]+.2-ethyl	mâ+âh]+.2-ethyl	JJ	O
methanesulphonate	methanesulphonate	NN	O
:	:	:	O
Methane	Methane	NNP	O
sulphonylchloride	sulphonylchloride	NN	O
was	be	VBD	O
added	add	VBN	O
dropwise	dropwise	NN	O
to	to	IN	O
a	a	DT	O
stirred	stir	VBN	O
solution	solution	NN	O
of	of	IN	O
metronidazole	metronidazole	NN	O
,	,	,	O
5	5	CD	O
,	,	,	O
triethylamine	triethylamine	NN	O
and	and	CC	O
DMAP	dmap	NN	O
in	in	IN	O
anhydrous	anhydrous	JJ	O
methylene	methylene	NN	O
chloride	chloride	NN	O
at	at	IN	O
0âÂ	0ââ	CD	O
°	°	NNS	O
C	C	NNP	O
.	.	.	O

The	the	DT	O
reaction	reaction	NN	O
mixture	mixture	NN	O
was	be	VBD	O
allowed	allow	VBN	O
to	to	TO	O
warm	warm	VB	O
to	to	TO	O
room	room	VB	O
temperature	temperature	NN	O
and	and	CC	O
stirred	stir	VBN	O
for	for	IN	O
overnight	overnight	RB	O
.	.	.	O

The	the	DT	O
reaction	reaction	NN	O
mixture	mixture	NN	O
was	be	VBD	O
diluted	dilute	VBN	O
with	with	IN	O
methylene	methylene	JJ	O
chloride	chloride	NN	O
and	and	CC	O
washed	wash	VBN	O
with	with	IN	O
water	water	NN	O
and	and	CC	O
brine	brine	NN	O
.	.	.	O

The	the	DT	O
organic	organic	JJ	O
layer	layer	NN	O
was	be	VBD	O
dried	dry	VBN	O
over	over	IN	O
anhydrous	anhydrous	JJ	O
sodium	sodium	NN	O
sulphate	sulphate	NN	O
,	,	,	O
filtered	filter	VBN	O
and	and	CC	O
evaporated	evaporate	VBD	O
to	to	TO	O
get	get	VB	O
crude	crude	JJ	O
compound	compound	NN	O
which	which	WDT	O
was	be	VBD	O
used	use	VBN	O
further	further	RB	O
without	without	IN	O
purification	purification	NN	O
.	.	.	O

Yield	yield	NN	O
:	:	:	O
quantitative	quantitative	JJ	O
.	.	.	O

1H	1H	NNP	O
NMR	NMR	NNP	O
DMSO	DMSO	NNP	O
-	-	HYPH	O
d6	d6	NN	O
,	,	,	O
400âMHz	400âmhz	CD	O
Î	Î	NNP	O
´	´	CD	O
8.05	8.05	CD	O
,	,	,	O
4.61	4.61	CD	O
t	t	NNP	O
,	,	,	O
Jâ=â7.3	Jâ=â7.3	NNP	O
,	,	,	O
2H	2H	NNP	O
,	,	,	O
3.51	3.51	CD	O
t	t	NNP	O
,	,	,	O
Jâ=â7.3	Jâ=â7.3	NNP	O
,	,	,	O
2H	2H	NNP	O
,	,	,	O
2.50	2.50	CD	O
;	;	:	O
13C	13C	NNP	O
NMR	NMR	NNP	O
DMSO	DMSO	NNP	O
-	-	HYPH	O
d6	d6	NN	O
,	,	,	O
101âMHz	101âmhz	LS	O
Î	Î	NNP	O
´	´	CD	O
151.08	151.08	CD	O
,	,	,	O
138.18	138.18	CD	O
,	,	,	O
133.14	133.14	CD	O
,	,	,	O
47.09	47.09	CD	O
,	,	,	O
14.09	14.09	CD	O
,	,	,	O
2.28	2.28	CD	O
.	.	.	O

MS	MS	NNP	O
m	m	NNP	O
/	/	SYM	O
z	z	NNP	O
281.97	281.97	CD	O
Mâ+âH]+	mâ+âh]+	RB	O
.	.	.	O

S-(2-ethyl	s-(2-ethyl	ADD	O
ethanethioate	ethanethioate	VB	O
:	:	:	O
Potassium	potassium	NN	O
thioacetate	thioacetate	NN	O
was	be	VBD	O
added	add	VBN	O
to	to	IN	O
a	a	DT	O
solution	solution	NN	O
of	of	IN	O
6	6	CD	O
in	in	IN	O
anhydrous	anhydrous	JJ	O
DMF	dmf	NN	O
and	and	CC	O
stirred	stir	VBD	O
at	at	IN	O
room	room	NN	O
temperature	temperature	NN	O
for	for	IN	O
16âh	16âh	CD	O
.	.	.	O

The	the	DT	O
reaction	reaction	NN	O
mixture	mixture	NN	O
was	be	VBD	O
then	then	RB	O
diluted	dilute	VBN	O
with	with	IN	O
ethyl	ethyl	NN	O
acetate	acetate	NNP	O
and	and	CC	O
washed	wash	VBD	O
with	with	IN	O
water	water	NN	O
and	and	CC	O
brine	brine	NN	O
.	.	.	O

The	the	DT	O
organic	organic	JJ	O
layer	layer	NN	O
was	be	VBD	O
dried	dry	VBN	O
over	over	IN	O
anhydrous	anhydrous	JJ	O
sodium	sodium	NN	O
sulphate	sulphate	NN	O
,	,	,	O
filtered	filter	VBN	O
and	and	CC	O
concentrated	concentrate	VBN	O
under	under	IN	O
vacuum	vacuum	NN	O
to	to	TO	O
give	give	VB	O
thioacetate	thioacetate	NN	O
7	7	CD	O
.	.	.	O

Yield	yield	NN	O
:	:	:	O
83	83	CD	O
%	%	NN	O
,	,	,	O
1H	1H	NNP	O
NMR	NMR	NNP	O
400âMHz	400âmhz	CD	O
,	,	,	O
DMSO	DMSO	NNP	O
-	-	HYPH	O
d6	d6	NN	O
Î	Î	NNP	O
´	´	CD	O
8.01	8.01	CD	O
,	,	,	O
4.45	4.45	CD	O
t	t	NNP	O
,	,	,	O
Jâ=â6.6	Jâ=â6.6	NNP	O
,	,	,	O
2H	2H	NNP	O
,	,	,	O
3.27	3.27	CD	O
t	t	NNP	O
,	,	,	O
Jâ=â6.6	Jâ=â6.6	NNP	O
,	,	,	O
2H	2H	NNP	O
,	,	,	O
2.46	2.46	CD	O
,	,	,	O
2.29	2.29	CD	O
.	.	.	O

13C	13c	CD	O
NMR	NMR	NNP	O
101âMHz	101âMHz	NNS	O
,	,	,	O
DMSO	DMSO	NNP	O
Î	Î	NNP	O
´	´	CD	O
194.59	194.59	CD	O
,	,	,	O
151.25	151.25	CD	O
,	,	,	O
138.42	138.42	CD	O
,	,	,	O
132.92	132.92	CD	O
,	,	,	O
44.68	44.68	CD	O
,	,	,	O
30.32	30.32	CD	O
,	,	,	O
27.87	27.87	CD	O
.	.	.	O

MS	MS	NNP	O
m	m	NNP	O
/	/	SYM	O
z	z	NNP	O
230.06	230.06	CD	O
Mâ+âH]+.2-ethane-1-sulphonyl	mâ+âh]+.2-ethane-1-sulphonyl	NN	O
chloride	chloride	NN	O
:	:	:	O
A	a	DT	O
solution	solution	NN	O
of	of	IN	O
7	7	CD	O
was	be	VBD	O
treated	treat	VBN	O
with	with	IN	O
hydrogen	hydrogen	NN	O
peroxide	peroxide	NN	O
35	35	CD	O
%	%	NN	O
w	w	NN	O
/	/	SYM	O
w	w	NN	O
in	in	IN	O
water	water	NN	O
6âml	6âml	CD	O
and	and	CC	O
acetic	acetic	JJ	O
acid	acid	NN	O
7âml	7âml	CD	O
.	.	.	O

The	the	DT	O
reaction	reaction	NN	O
mixture	mixture	NN	O
was	be	VBD	O
allowed	allow	VBN	O
to	to	TO	O
stir	stir	VB	O
for	for	IN	O
24âh	24âh	CD	O
at	at	IN	O
room	room	NN	O
temperature	temperature	NN	O
;	;	:	O
the	the	DT	O
excess	excess	JJ	O
hydrogen	hydrogen	NN	O
peroxide	peroxide	NN	O
was	be	VBD	O
quenched	quench	VBN	O
by	by	IN	O
addition	addition	NN	O
of	of	IN	O
10	10	CD	O
%	%	NN	O
Pd	Pd	NNP	O
/	/	SYM	O
C	C	NNP	O
0.050âg	0.050âg	NN	O
.	.	.	O

The	the	DT	O
mixture	mixture	NN	O
was	be	VBD	O
filtered	filter	VBN	O
on	on	IN	O
celite	celite	NNP	O
,	,	,	O
concentrated	concentrate	VBD	O
,	,	,	O
and	and	CC	O
co	co	NNS	O
-	-	VBN	O
evaporated	evaporate	VBD	O
with	with	IN	O
toluene	toluene	JJ	O
.	.	.	O

The	the	DT	O
obtained	obtained	JJ	O
sulphonic	sulphonic	JJ	O
acid	acid	NN	O
was	be	VBD	O
used	use	VBN	O
further	further	RB	O
without	without	IN	O
purification	purification	NN	O
.	.	.	O

The	the	DT	O
crude	crude	JJ	O
2-ethane-1-sulphonic	2-ethane-1-sulphonic	CD	O
acid	acid	NN	O
8	8	CD	O
was	be	VBD	O
suspended	suspend	VBN	O
in	in	IN	O
anhydrous	anhydrous	JJ	O
DCM	DCM	NNP	O
and	and	CC	O
a	a	DT	O
solution	solution	NN	O
of	of	IN	O
phosgene	phosgene	NN	O
in	in	IN	O
toluene	toluene	JJ	O
20	20	CD	O
%	%	NN	O
wt	wt	NNP	O
.	.	NNP	O

,	,	,	O
3.5âml	3.5âml	CD	O
and	and	CC	O
dry	dry	JJ	O
DMF	dmf	NN	O
1âml	1âml	CD	O
was	be	VBD	O
added	add	VBN	O
under	under	IN	O
argon	argon	NNP	O
atmosphere	atmosphere	NN	O
.	.	.	O

After	after	IN	O
1âh	1âh	CD	O
an	an	DT	O
additional	additional	JJ	O
1âml	1âml	CD	O
phosgene	phosgene	NN	O
solution	solution	NN	O
was	be	VBD	O
added	add	VBN	O
,	,	,	O
and	and	CC	O
the	the	DT	O
mixture	mixture	NN	O
was	be	VBD	O
stirred	stir	VBN	O
for	for	IN	O
2âh	2âh	CD	O
under	under	IN	O
same	same	JJ	O
conditions	condition	NNS	O
.	.	.	O

After	after	IN	O
precipitation	precipitation	NN	O
,	,	,	O
the	the	DT	O
reaction	reaction	NN	O
mixture	mixture	NN	O
was	be	VBD	O
filtered	filter	VBN	O
to	to	TO	O
get	get	VB	O
pure	pure	JJ	O
compound	compound	NN	O
9	9	CD	O
as	as	IN	O
solid	solid	JJ	O
.	.	.	O

Yield	yield	NN	O
:	:	:	O
66	66	CD	O
%	%	NN	O
,	,	,	O
1H	1H	NNP	O
NMR	NMR	NNP	O
400âMHz	400âmhz	CD	O
,	,	,	O
DMSO	DMSO	NNP	O
-	-	HYPH	O
d6	d6	NN	O
Î	Î	NNP	O
´	´	CD	O
8.80	8.80	CD	O
,	,	,	O
4.63	4.63	CD	O
t	t	NNP	O
,	,	,	O
Jâ=â6.3	jâ=â6.3	UH	O
,	,	,	O
2H	2H	NNP	O
,	,	,	O
2.92	2.92	NNP	O
t	t	NNP	O
,	,	,	O
Jâ=â6.3	jâ=â6.3	UH	O
,	,	,	O
2H	2H	NNP	O
,	,	,	O
2.78	2.78	CD	O
,	,	,	O
13C	13C	NNP	O
NMR	NMR	NNP	O
101âMHz	101âmhz	CD	O
,	,	,	O
DMSO	DMSO	NNP	O
-	-	HYPH	O
d6	d6	NN	O
Î	Î	NNP	O
´	´	CD	O
149.90	149.90	CD	O
,	,	,	O
138.05	138.05	CD	O
,	,	,	O
123.91	123.91	CD	O
,	,	,	O
48.67	48.67	CD	O
,	,	,	O
44.17	44.17	CD	O
,	,	,	O
12.13	12.13	CD	O
.	.	.	O

MS	MS	NNP	O
m	m	NNP	O
/	/	SYM	O
z	z	NNP	O
236.00	236.00	CD	O
Mâ+âH]+	mâ+âh]+	RB	O
.	.	.	O

An	an	DT	O
Applied	Applied	NNP	O
Photophysics	Photophysics	NNPS	O
stopped	stop	VBD	O
-	-	HYPH	O
flow	flow	NN	O
instrument	instrument	NN	O
was	be	VBD	O
used	use	VBN	O
for	for	IN	O
assaying	assay	VBG	O
the	the	DT	O
CA	CA	NNP	O
-	-	HYPH	O
catalyzed	catalyze	VBN	O
CO2	CO2	NNP	O
hydration	hydration	NN	O
activity	activity	NN	B
.	.	.	O

Phenol	Phenol	NNP	O
red	red	JJ	O
at	at	IN	O
a	a	DT	O
concentration	concentration	NN	O
of	of	IN	O
0.2âmM	0.2âmm	NN	O
was	be	VBD	O
used	use	VBN	O
as	as	IN	O
an	an	DT	O
indicator	indicator	NN	O
,	,	,	O
working	work	VBG	O
at	at	IN	O
the	the	DT	O
absorbance	absorbance	NN	O
maximum	maximum	NN	O
of	of	IN	O
557ânm	557ânm	CD	O
,	,	,	O
with	with	IN	O
20âmM	20âmm	CD	O
Hepes	Hepes	NNPS	O
as	as	IN	O
buffer	buffer	NN	O
and	and	CC	O
20âmM	20âmm	CD	O
Na2SO4	Na2SO4	NNP	O
,	,	,	O
following	follow	VBG	O
the	the	DT	O
initial	initial	JJ	O
rates	rate	NNS	O
of	of	IN	O
the	the	DT	O
CA	CA	NNP	O
-	-	HYPH	O
catalysed	catalyse	VBN	O
CO2	CO2	NNP	O
hydration	hydration	NN	O
reaction	reaction	NN	O
for	for	IN	O
a	a	DT	O
period	period	NN	O
of	of	IN	O
10â100âs	10â100âs	CD	O
.	.	.	O

The	the	DT	O
CO2	CO2	NNP	O
concentrations	concentration	NNS	O
ranged	range	VBD	O
from	from	IN	O
1.7	1.7	CD	O
to	to	TO	O
17âmM	17âmm	CD	O
for	for	IN	O
the	the	DT	O
determination	determination	NN	O
of	of	IN	O
the	the	DT	O
kinetic	kinetic	JJ	O
parameters	parameter	NNS	O
and	and	CC	O
inhibition	inhibition	NN	O
constants	constant	NNS	O
.	.	.	O

For	for	IN	O
each	each	DT	O
inhibitor	inhibitor	NN	O
,	,	,	O
at	at	IN	O
least	least	JJS	O
six	six	CD	O
traces	trace	NNS	O
of	of	IN	O
the	the	DT	O
initial	initial	JJ	O
5â10	5â10	CD	O
%	%	NN	O
of	of	IN	O
the	the	DT	O
reaction	reaction	NN	O
were	be	VBD	O
used	use	VBN	O
for	for	IN	O
determining	determine	VBG	O
the	the	DT	O
initial	initial	JJ	O
velocity	velocity	NN	O
.	.	.	O

The	the	DT	O
uncatalysed	uncatalysed	JJ	O
rates	rate	NNS	O
were	be	VBD	O
determined	determine	VBN	O
in	in	IN	O
the	the	DT	O
same	same	JJ	O
manner	manner	NN	O
and	and	CC	O
subtracted	subtract	VBD	O
from	from	IN	O
the	the	DT	O
total	total	JJ	O
observed	observed	JJ	O
rates	rate	NNS	O
.	.	.	O

Stock	stock	NN	O
solutions	solution	NNS	O
of	of	IN	O
inhibitor	inhibitor	NN	O
0.1âmM	0.1âmm	CD	O
were	be	VBD	O
prepared	prepare	VBN	O
in	in	IN	O
distilled	distil	VBN	O
-	-	HYPH	O
deionized	deionize	VBN	O
water	water	NN	O
,	,	,	O
and	and	CC	O
dilutions	dilution	NNS	O
up	up	RB	O
to	to	IN	O
0.01ânM	0.01ânm	NN	O
were	be	VBD	O
done	do	VBN	O
thereafter	thereafter	RB	O
with	with	IN	O
distilled	distil	VBN	O
-	-	HYPH	O
deionized	deionize	VBN	O
water	water	NN	O
.	.	.	O

Inhibitor	inhibitor	NN	O
and	and	CC	O
enzyme	enzyme	NNS	O
solutions	solution	NNS	O
were	be	VBD	O
pre	pre	VBN	O
-	-	VBN	O
incubated	incubate	VBN	O
together	together	RB	O
for	for	IN	O
15âmin	15âmin	CD	O
at	at	IN	O
room	room	NN	O
temperature	temperature	NN	O
prior	prior	RB	O
to	to	IN	O
assay	assay	NNP	O
to	to	TO	O
allow	allow	VB	O
for	for	IN	O
the	the	DT	O
formation	formation	NN	O
of	of	IN	O
the	the	DT	O
E	e	NN	O
-	-	:	O
I	-PRON-	PRP	O
complex	complex	NN	O
.	.	.	O

The	the	DT	O
inhibition	inhibition	NN	O
constants	constant	NNS	O
were	be	VBD	O
obtained	obtain	VBN	O
by	by	IN	O
non	non	JJ	O
-	-	JJ	O
linear	linear	JJ	O
least	least	JJS	O
-	-	HYPH	O
squares	square	NNS	O
methods	method	NNS	O
using	use	VBG	O
PRISM	PRISM	NNP	O
3	3	CD	O
and	and	CC	O
represent	represent	VB	O
the	the	DT	O
average	average	NN	O
from	from	IN	O
at	at	RB	O
least	least	RBS	O
three	three	CD	O
different	different	JJ	O
determinations	determination	NNS	O
.	.	.	O

CA	CA	NNP	O
isoforms	isoform	NNS	O
were	be	VBD	O
recombinant	recombinant	JJ	O
ones	one	NNS	O
obtained	obtain	VBN	O
in	in	IN	O
house	house	NN	O
as	as	IN	O
reported	report	VBN	O
earlier	early	RBR	O
.	.	.	O

The	the	DT	O
three	three	CD	O
compounds	compound	NNS	O
3	3	CD	O
,	,	,	O
4	4	CD	O
and	and	CC	O
10	10	CD	O
were	be	VBD	O
designed	design	VBN	O
and	and	CC	O
synthesised	synthesise	VBN	O
with	with	IN	O
the	the	DT	O
purpose	purpose	NN	O
of	of	IN	O
developing	develop	VBG	O
them	-PRON-	PRP	O
as	as	IN	O
inhibitors	inhibitor	NNS	O
of	of	IN	O
human	human	JJ	O
CAs	ca	NNS	O
.	.	.	O

Subsequently	subsequently	RB	O
,	,	,	O
all	all	PDT	O
the	the	DT	O
three	three	CD	O
compounds	compound	NNS	O
were	be	VBD	O
investigated	investigate	VBN	O
inÂ	inÂ	NNP	O
vitro	vitro	FW	O
as	as	IN	O
inhibitors	inhibitor	NNS	O
of	of	IN	O
human	human	JJ	O
CA	CA	NNP	O
I	I	NNP	O
,	,	,	O
CA	CA	NNP	O
II	II	NNP	O
and	and	CC	O
CA	CA	NNP	O
IX	IX	NNP	O
.	.	.	O

These	these	DT	O
compounds	compound	NNS	O
were	be	VBD	O
dissolved	dissolve	VBN	O
in	in	IN	O
dimethyl	dimethyl	NNP	O
sulphoxide	sulphoxide	NNP	O
to	to	TO	O
prepare	prepare	VB	O
100âmM	100âmm	CD	O
stock	stock	NN	O
solutions	solution	NNS	O
.	.	.	O

Before	before	IN	O
start	start	NN	O
of	of	IN	O
each	each	DT	O
experiment	experiment	NN	O
,	,	,	O
the	the	DT	O
series	series	NN	O
of	of	IN	O
dilatation	dilatation	NN	O
were	be	VBD	O
made	make	VBN	O
from	from	IN	O
the	the	DT	O
above	above	JJ	O
stock	stock	NN	O
in	in	IN	O
an	an	DT	O
embryonic	embryonic	JJ	O
medium	medium	NN	O
5.0âmM	5.0âmm	CD	O
NaCl	NaCl	NNP	O
,	,	,	O
0.17âmM	0.17âmm	CD	O
KCl	KCl	NNS	O
,	,	,	O
0.33âmM	0.33âmm	NN	O
CaCl2	cacl2	NN	O
,	,	,	O
0.33âmM	0.33âmm	NN	O
MgSO4	MgSO4	NNP	O
,	,	,	O
and	and	CC	O
0.1	0.1	CD	O
%	%	NN	O
w	w	NN	O
/	/	SYM	O
v	v	NN	O
Methylene	Methylene	NNP	O
Blue	Blue	NNP	O
.	.	.	O

Embryos	embryo	NNS	O
after	after	IN	O
1-day	1-day	CD	O
post	post	NN	O
fertilisation	fertilisation	NN	O
were	be	VBD	O
exposed	expose	VBN	O
the	the	DT	O
each	each	DT	O
of	of	IN	O
the	the	DT	O
diluted	diluted	JJ	O
inhibitor	inhibitor	NN	O
solution	solution	NN	O
.	.	.	O

AB	AB	NNP	O
strains	strain	NNS	O
of	of	IN	O
wild	wild	JJ	O
-	-	HYPH	O
type	type	NN	O
adult	adult	NN	O
zebrafish	zebrafish	NNPS	O
were	be	VBD	O
maintained	maintain	VBN	O
at	at	IN	O
28.5âÂ	28.5ââ	CD	O
°	°	,	O
C	C	NNP	O
in	in	IN	O
an	an	DT	O
incubator	incubator	NN	B
.	.	.	O

For	for	IN	O
collecting	collect	VBG	O
embryos	embryo	NNS	O
,	,	,	O
3â5	3â5	CD	O
pairs	pair	NNS	O
of	of	IN	O
male	male	JJ	O
and	and	CC	O
female	female	JJ	O
fish	fish	NNS	O
were	be	VBD	O
set	set	VBN	O
up	up	RP	O
overnight	overnight	RB	O
for	for	IN	O
breeding	breed	VBG	B
.	.	.	O

The	the	DT	O
next	next	JJ	O
morning	morning	NN	O
,	,	,	O
from	from	IN	O
the	the	DT	O
overnight	overnight	JJ	O
breeding	breeding	NN	O
tanks	tank	NNS	O
1â2-h	1â2-h	VBZ	O
post	post	NNP	O
fertilisation	fertilisation	NN	O
embryos	embryo	NNS	O
were	be	VBD	O
collected	collect	VBN	O
in	in	IN	O
a	a	DT	O
sieve	sieve	NN	O
and	and	CC	O
rinsed	rinse	VBN	O
with	with	IN	O
embryonic	embryonic	JJ	O
medium	medium	NN	O
5.0âmM	5.0âmm	CD	O
NaCl	NaCl	NNP	O
,	,	,	O
0.17âmM	0.17âmm	CD	O
KCl	KCl	NNS	O
,	,	,	O
0.33âmM	0.33âmm	NN	O
CaCl2	cacl2	NN	O
,	,	,	O
0.33âmM	0.33âmm	NN	O
MgSO4	MgSO4	NNP	O
,	,	,	O
and	and	CC	O
0.1	0.1	CD	O
%	%	NN	O
w	w	NN	O
/	/	SYM	O
v	v	NN	O
Methylene	Methylene	NNP	O
Blue	Blue	NNP	O
and	and	CC	O
kept	keep	VBD	O
the	the	DT	O
collected	collect	VBN	O
embryos	embryo	NNS	O
in	in	IN	O
an	an	DT	O
incubator	incubator	NN	O
at	at	IN	O
28.5âÂ	28.5ââ	CD	O
°	°	,	O
C	C	NNP	O
overnight	overnight	RB	O
.	.	.	O

The	the	DT	O
toxicity	toxicity	NN	O
evaluation	evaluation	NN	O
studies	study	NNS	O
of	of	IN	O
the	the	DT	O
inhibitors	inhibitor	NNS	O
were	be	VBD	O
performed	perform	VBN	O
using	use	VBG	O
the	the	DT	O
fish	fish	NN	O
that	that	WDT	O
were	be	VBD	O
24	24	CD	O
hpf	hpf	NN	O
.	.	.	O

All	all	PDT	O
the	the	DT	O
zebrafish	zebrafish	JJ	O
experiments	experiment	NNS	O
were	be	VBD	O
performed	perform	VBN	O
at	at	IN	O
the	the	DT	O
zebrafish	zebrafish	JJ	O
core	core	NN	O
facility	facility	NN	O
,	,	,	O
Tampere	Tampere	NNP	O
University	University	NNP	O
,	,	,	O
Finland	Finland	NNP	O
and	and	CC	O
according	accord	VBG	O
to	to	IN	O
the	the	DT	O
protocol	protocol	NN	O
used	use	VBN	O
in	in	IN	O
our	-PRON-	PRP$	O
laboratory	laboratory	NN	B
.	.	.	O

Tampere	Tampere	NNP	O
University	University	NNP	O
has	have	VBZ	O
an	an	DT	O
established	established	JJ	O
zebrafish	zebrafish	JJ	O
core	core	NN	O
facility	facility	NN	O
authorisation	authorisation	NN	O
granted	grant	VBN	O
by	by	IN	O
the	the	DT	O
National	National	NNP	O
Animal	Animal	NNP	O
Experiment	Experiment	NNP	O
Board	Board	NNP	O
.	.	.	O

The	the	DT	O
experiments	experiment	NNS	O
using	use	VBG	O
developing	develop	VBG	O
zebrafish	zebrafish	JJ	O
embryos	embryo	NNS	O
were	be	VBD	O
performed	perform	VBN	O
according	accord	VBG	O
to	to	IN	O
the	the	DT	O
Provincial	Provincial	NNP	O
Government	Government	NNP	O
of	of	IN	O
Eastern	Eastern	NNP	O
Finland	Finland	NNP	O
Province	Province	NNP	O
Social	Social	NNP	O
and	and	CC	O
Health	Health	NNP	O
Department	Department	NNP	O
Tampere	Tampere	NNP	O
Regional	Regional	NNP	O
Service	Service	NNP	O
Unit	Unit	NNP	O
protocol	protocol	NN	O
#	#	$	O
LSLH-2007â7254	LSLH-2007â7254	NNP	O
/	/	SYM	O
Ym-23	Ym-23	NNP	O
.	.	.	O

Care	care	NN	O
was	be	VBD	O
taken	take	VBN	O
to	to	TO	O
ameliorate	ameliorate	VB	O
suffering	suffering	NN	O
by	by	IN	O
euthanizing	euthanize	VBG	O
the	the	DT	O
5	5	CD	O
dpf	dpf	NN	O
larvae	larvae	VBN	O
by	by	IN	O
prolonged	prolonged	JJ	O
immersion	immersion	NN	O
in	in	IN	O
a	a	DT	O
petri	petri	JJ	O
dish	dish	NN	O
containing	contain	VBG	O
an	an	DT	O
overdose	overdose	NN	O
of	of	IN	O
Tricaine	Tricaine	NNP	O
before	before	IN	O
fixing	fix	VBG	O
in	in	IN	O
buffered	buffered	JJ	O
formaldehyde	formaldehyde	NN	O
for	for	IN	O
histochemical	histochemical	JJ	O
analysis	analysis	NN	O
.	.	.	O

The	the	DT	O
LC50	LC50	NNP	O
values	value	NNS	O
of	of	IN	O
the	the	DT	O
compounds	compound	NNS	O
3	3	CD	O
,	,	,	O
4	4	CD	O
and	and	CC	O
10	10	CD	O
were	be	VBD	O
determined	determine	VBN	O
using	use	VBG	O
1-dpf	1-dpf	NNP	O
embryos	embryo	NNS	O
exposed	expose	VBN	O
to	to	IN	O
10â12	10â12	CD	O
different	different	JJ	O
inhibitor	inhibitor	NN	O
concentrations	concentration	NNS	O
.	.	.	O

For	for	IN	O
each	each	DT	O
concentration	concentration	NN	O
of	of	IN	O
the	the	DT	O
inhibitor	inhibitor	NN	O
,	,	,	O
we	-PRON-	PRP	O
used	use	VBD	O
30	30	CD	O
1dpf	1dpf	CD	O
larvae	larvae	JJ	B
,	,	,	B
.	.	.	O

In	in	IN	O
each	each	DT	O
group	group	NN	O
,	,	,	O
the	the	DT	O
larvae	larva	NNS	O
were	be	VBD	O
exposed	expose	VBN	O
to	to	IN	O
different	different	JJ	O
concentrations	concentration	NNS	O
of	of	IN	O
the	the	DT	O
inhibitors	inhibitor	NNS	O
that	that	WDT	O
ranged	range	VBD	O
from	from	IN	O
12.5âÂµM	12.5ââµm	CD	O
to	to	IN	O
3âmM.	3âmm.	CD	O
The	the	DT	O
dose	dose	JJ	O
response	response	NN	O
curve	curve	NN	O
was	be	VBD	O
calculated	calculate	VBN	O
using	use	VBG	O
DRM	DRM	NNP	O
of	of	IN	O
the	the	DT	O
DRC	DRC	NNP	O
R	r	NN	O
package	package	NN	B
.	.	.	O

The	the	DT	O
control	control	NN	O
group	group	NN	O
was	be	VBD	O
constituted	constitute	VBN	O
of	of	IN	O
an	an	DT	O
equal	equal	JJ	O
number	number	NN	O
of	of	IN	O
larvae	larvae	NNP	O
not	not	RB	O
treated	treat	VBN	O
with	with	IN	O
any	any	DT	O
chemical	chemical	NN	O
and	and	CC	O
the	the	DT	O
larvae	larva	NNS	O
that	that	WDT	O
were	be	VBD	O
treated	treat	VBN	O
with	with	IN	O
1	1	CD	O
%	%	NN	O
of	of	IN	O
DMSO	DMSO	NNP	O
.	.	.	O

Toxicological	toxicological	JJ	O
evaluation	evaluation	NN	O
studies	study	NNS	O
were	be	VBD	O
performed	perform	VBN	O
in	in	IN	O
24-well	24-well	CD	O
plates	plate	NNS	O
.	.	.	O

In	in	IN	O
each	each	DT	O
well	well	RB	O
,	,	,	O
we	-PRON-	PRP	O
placed	place	VBD	O
1â2	1â2	RP	O
1-dpf	1-dpf	CD	O
embryos	embryo	NNS	O
in	in	IN	O
1âml	1âml	CD	O
of	of	IN	O
embryonic	embryonic	JJ	O
medium	medium	NN	O
containing	contain	VBG	O
a	a	DT	O
diluted	diluted	JJ	O
inhibitor	inhibitor	NN	O
.	.	.	O

For	for	IN	O
control	control	NN	O
groups	group	NNS	O
,	,	,	O
1	1	CD	O
%	%	NN	O
DMSO	DMSO	NNP	O
diluted	dilute	VBN	O
in	in	IN	O
either	either	DT	O
embryonic	embryonic	JJ	O
medium	medium	JJ	O
or	or	CC	O
embryonic	embryonic	JJ	O
medium	medium	NN	O
with	with	IN	O
no	no	DT	O
chemical	chemical	JJ	O
compound	compound	NN	O
.	.	.	O

A	a	DT	O
minimum	minimum	NN	O
of	of	IN	O
three	three	CD	O
sets	set	NNS	O
of	of	IN	O
experiments	experiment	NNS	O
were	be	VBD	O
carried	carry	VBN	O
out	out	RP	O
for	for	IN	O
each	each	DT	O
inhibitor	inhibitor	NN	O
.	.	.	O

The	the	DT	O
mortality	mortality	NN	O
of	of	IN	O
the	the	DT	O
larvae	larvae	NN	O
was	be	VBD	O
checked	check	VBN	O
every	every	DT	O
24âh	24âh	CD	O
until	until	IN	O
5âd	5âd	CD	O
after	after	IN	O
exposure	exposure	NN	O
to	to	IN	O
the	the	DT	O
inhibitors	inhibitor	NNS	O
.	.	.	O

We	-PRON-	PRP	O
assessed	assess	VBD	O
the	the	DT	O
effect	effect	NN	O
of	of	IN	O
inhibitors	inhibitor	NNS	O
on	on	IN	O
the	the	DT	O
zebrafish	zebrafish	NNP	O
larvae	larvae	NNP	O
after	after	IN	O
5âd	5âd	CD	O
of	of	IN	O
exposure	exposure	NN	O
to	to	IN	O
the	the	DT	O
drugs	drug	NNS	O
;	;	:	O
we	-PRON-	PRP	O
analysed	analyse	VBD	O
eight	eight	CD	O
observable	observable	JJ	O
phenotypic	phenotypic	JJ	O
parameters	parameter	NNS	O
:	:	:	O
mortality	mortality	NN	O
,	,	,	O
hatching	hatching	NN	O
,	,	,	O
oedema	oedema	NN	O
,	,	,	O
movement	movement	NN	O
pattern	pattern	NN	O
,	,	,	O
yolk	yolk	NNP	O
sack	sack	NN	O
utilisation	utilisation	NN	O
,	,	,	O
heartbeat	heartbeat	NN	O
,	,	,	O
body	body	NN	O
shape	shape	NN	O
and	and	CC	O
swim	swim	VB	O
bladder	bladder	NN	O
development	development	NN	O
,	,	,	O
using	use	VBG	O
a	a	DT	O
stereo	stereo	NN	O
microscope	microscope	NN	O
and	and	CC	O
recorded	record	VBD	O
the	the	DT	O
observations	observation	NNS	O
for	for	IN	O
each	each	DT	O
inhibitor	inhibitor	NN	O
treated	treat	VBN	O
and	and	CC	O
control	control	NN	O
groups	group	NNS	O
.	.	.	O

The	the	DT	O
images	image	NNS	O
of	of	IN	O
the	the	DT	O
developing	develop	VBG	O
larvae	larva	NNS	O
were	be	VBD	O
taken	take	VBN	O
using	use	VBG	O
a	a	DT	O
Lumar	Lumar	NNP	O
V1.12	V1.12	NNP	O
fluorescence	fluorescence	NN	O
microscope	microscope	NN	O
attached	attach	VBD	O
to	to	IN	O
a	a	DT	O
camera	camera	NN	O
with	with	IN	O
a	a	DT	O
1.5	1.5	CD	O
lens	lens	NN	O
Carl	Carl	NNP	O
Zeiss	Zeiss	NNP	O
MicroImaging	MicroImaging	NNP	O
GmbH	GmbH	NNP	O
,	,	,	O
GÃ¶ttingen	GÃ¶ttingen	NNP	O
,	,	,	O
Germany	Germany	NNP	O
.	.	.	O

The	the	DT	O
images	image	NNS	O
were	be	VBD	O
analysed	analyse	VBN	O
with	with	IN	O
AxioVision	AxioVision	NNP	O
software	software	NN	O
versions	version	NNS	O
4.7	4.7	CD	O
and	and	CC	O
4.8	4.8	CD	O
as	as	IN	O
described	describe	VBN	O
in	in	IN	O
our	-PRON-	PRP$	O
standard	standard	JJ	O
protocol	protocol	NN	O
for	for	IN	O
assessment	assessment	NN	O
of	of	IN	O
toxicity	toxicity	NN	O
and	and	CC	O
safety	safety	NN	O
of	of	IN	O
the	the	DT	O
chemical	chemical	NN	O
compounds	compound	NNS	B
.	.	.	O

The	the	DT	O
movement	movement	NN	O
of	of	IN	O
the	the	DT	O
zebrafish	zebrafish	NNP	O
larvae	larvae	NNP	O
was	be	VBD	O
tracked	track	VBN	O
from	from	IN	O
day	day	NN	O
4	4	CD	O
of	of	IN	O
exposure	exposure	NN	O
to	to	IN	O
these	these	DT	O
inhibitors	inhibitor	NNS	O
.	.	.	O

Similarly	similarly	RB	O
,	,	,	O
detailed	detailed	JJ	O
analysis	analysis	NN	O
of	of	IN	O
the	the	DT	O
swim	swim	NN	O
pattern	pattern	NN	O
of	of	IN	O
the	the	DT	O
larvae	larvae	NNP	O
was	be	VBD	O
performed	perform	VBN	O
at	at	IN	O
the	the	DT	O
end	end	NN	O
of	of	IN	O
day	day	NN	O
5	5	CD	O
after	after	IN	O
exposure	exposure	NN	O
to	to	IN	O
the	the	DT	O
inhibitors	inhibitor	NNS	O
.	.	.	O

For	for	IN	O
analyses	analysis	NNS	O
of	of	IN	O
movement	movement	NN	O
pattern	pattern	NN	O
,	,	,	O
about	about	RB	O
10â15	10â15	CD	O
the	the	DT	O
zebrafish	zebrafish	NNP	O
larvae	larva	NNS	O
were	be	VBD	O
placed	place	VBN	O
in	in	IN	O
a	a	DT	O
35âmm	35âmm	CD	O
Ã	Ã	NNP	O
15âmm	15âmm	CD	O
petri	petri	NNP	O
dish	dish	NNP	O
containing	contain	VBG	O
embryonic	embryonic	JJ	O
medium	medium	NN	O
and	and	CC	O
the	the	DT	O
larvae	larva	NNS	O
were	be	VBD	O
allowed	allow	VBN	O
to	to	TO	O
settle	settle	VB	O
in	in	IN	O
the	the	DT	O
petri	petri	JJ	O
dish	dish	NN	O
for	for	IN	O
1âmin	1âmin	NNS	O
.	.	.	O

The	the	DT	O
movement	movement	NN	O
of	of	IN	O
the	the	DT	O
zebrafish	zebrafish	NNP	O
larvae	larvae	NNP	O
was	be	VBD	O
observed	observe	VBN	O
under	under	IN	O
the	the	DT	O
microscope	microscope	NN	O
for	for	IN	O
1âmin	1âmin	CD	O
.	.	.	O

A	a	DT	O
short	short	JJ	O
video	video	NN	O
of	of	IN	O
about	about	IN	O
1âmin	1âmin	CD	O
was	be	VBD	O
taken	take	VBN	O
for	for	IN	O
each	each	DT	O
group	group	NN	O
of	of	IN	O
larvae	larvae	NNP	O
that	that	WDT	O
were	be	VBD	O
treated	treat	VBN	O
with	with	IN	O
125âÂµM	125ââµm	CD	O
concentration	concentration	NN	O
.	.	.	O

The	the	DT	O
swim	swim	NN	O
patterns	pattern	NNS	O
were	be	VBD	O
compared	compare	VBN	O
with	with	IN	O
the	the	DT	O
control	control	NN	O
group	group	NN	O
zebrafish	zebrafish	NNP	O
larvae	larvae	NNP	O
that	that	WDT	O
were	be	VBD	O
not	not	RB	O
treated	treat	VBN	O
with	with	IN	O
any	any	DT	O
inhibitor	inhibitor	NN	O
.	.	.	O

The	the	DT	O
histological	histological	JJ	O
analyses	analysis	NNS	O
were	be	VBD	O
done	do	VBN	O
to	to	TO	O
check	check	VB	O
the	the	DT	O
effect	effect	NN	O
of	of	IN	O
inhibitors	inhibitor	NNS	O
on	on	IN	O
the	the	DT	O
internal	internal	JJ	O
tissues	tissue	NNS	O
of	of	IN	O
the	the	DT	O
larvae	larva	NNS	O
that	that	WDT	O
were	be	VBD	O
treated	treat	VBN	O
with	with	IN	O
different	different	JJ	O
concentrations	concentration	NNS	O
of	of	IN	O
the	the	DT	O
inhibitors	inhibitor	NNS	O
used	use	VBN	O
in	in	IN	O
the	the	DT	O
study	study	NN	O
and	and	CC	O
the	the	DT	O
control	control	NN	O
group	group	NN	O
larvae	larvae	NNP	O
not	not	RB	O
treated	treat	VBN	O
with	with	IN	O
any	any	DT	O
inhibitor	inhibitor	NN	O
and	and	CC	O
the	the	DT	O
larvae	larvae	NN	O
treated	treat	VBN	O
with	with	IN	O
1	1	CD	O
%	%	NN	O
DMSO	DMSO	NNS	O
.	.	.	O

After	after	IN	O
5âd	5âd	CD	O
of	of	IN	O
exposure	exposure	NN	O
to	to	IN	O
different	different	JJ	O
concentration	concentration	NN	O
of	of	IN	O
the	the	DT	O
inhibitors	inhibitor	NNS	O
,	,	,	O
the	the	DT	O
larvae	larva	NNS	O
were	be	VBD	O
washed	wash	VBN	O
with	with	IN	O
phosphate	phosphate	NN	O
buffered	buffered	JJ	O
saline	saline	NN	O
immersed	immerse	VBN	O
in	in	IN	O
excess	excess	JJ	O
amounts	amount	NNS	O
of	of	IN	O
Tricaine	Tricaine	NNP	O
to	to	TO	O
anaesthetize	anaesthetize	VB	O
the	the	DT	O
larvae	larvae	NN	O
.	.	.	O

The	the	DT	O
larvae	larvae	NN	O
thus	thus	RB	O
prepared	prepared	JJ	O
were	be	VBD	O
transferred	transfer	VBN	O
to	to	IN	O
a	a	DT	O
1.5âml	1.5âml	CD	O
microcentrifuge	microcentrifuge	NN	O
tube	tube	NN	O
and	and	CC	O
fixed	fix	VBN	O
in	in	IN	O
buffered	buffered	JJ	O
formaldehyde	formaldehyde	NN	O
in	in	IN	O
PBS	PBS	NNP	O
for	for	IN	O
3âh	3âh	CD	O
at	at	IN	O
room	room	NN	O
temperature	temperature	NN	O
or	or	CC	O
overnight	overnight	RB	O
at	at	IN	O
4âÂ	4ââ	CD	O
°	°	,	O
C	C	NNP	O
.	.	.	O

After	after	IN	O
the	the	DT	O
fixation	fixation	NN	O
,	,	,	O
the	the	DT	O
larvae	larva	NNS	O
were	be	VBD	O
transferred	transfer	VBN	O
to	to	IN	O
70	70	CD	O
%	%	NN	O
ethanol	ethanol	NN	O
and	and	CC	O
stored	store	VBD	O
at	at	IN	O
4âÂ	4ââ	CD	O
°	°	,	O
C	C	NNP	O
before	before	IN	O
being	be	VBG	O
embedded	embed	VBN	O
in	in	IN	O
paraffin	paraffin	NN	O
.	.	.	O

The	the	DT	O
paraffin	paraffin	NN	O
-	-	HYPH	O
embedded	embed	VBN	O
samples	sample	NNS	O
were	be	VBD	O
sectioned	section	VBN	O
into	into	IN	O
5âÂµM	5ââµm	CD	O
thin	thin	JJ	O
slices	slice	NNS	O
for	for	IN	O
the	the	DT	O
histochemical	histochemical	JJ	O
staining	staining	NN	O
.	.	.	O

The	the	DT	O
fixed	fix	VBN	O
sections	section	NNS	O
containing	contain	VBG	O
samples	sample	NNS	O
were	be	VBD	O
deparaffinised	deparaffinise	VBN	O
in	in	IN	O
xylene	xylene	NNP	O
,	,	,	O
rehydrated	rehydrate	VBN	O
in	in	IN	O
an	an	DT	O
alcohol	alcohol	NN	O
series	series	NN	O
,	,	,	O
and	and	CC	O
stained	stain	VBN	O
with	with	IN	O
Mayer	Mayer	NNP	O
's	's	POS	O
Haematoxylin	Haematoxylin	NNP	O
and	and	CC	O
Eosin	Eosin	NNP	O
Y	Y	NNP	O
.	.	.	O

After	after	IN	O
dehydration	dehydration	NN	O
,	,	,	O
the	the	DT	O
slides	slide	NNS	O
were	be	VBD	O
mounted	mount	VBN	O
with	with	IN	O
EntellanÂ	EntellanÂ	NNP	O
®	®	.	O
Neu	Neu	NNP	O
.	.	.	O

The	the	DT	O
slides	slide	NNS	O
containing	contain	VBG	O
the	the	DT	O
tissues	tissue	NNS	O
were	be	VBD	O
examined	examine	VBN	O
for	for	IN	O
morphological	morphological	JJ	O
changes	change	NNS	O
in	in	IN	O
the	the	DT	O
tissues	tissue	NNS	O
of	of	IN	O
the	the	DT	O
larvae	larvae	NNP	O
exposed	expose	VBN	O
to	to	IN	O
the	the	DT	O
drugs	drug	NNS	O
and	and	CC	O
photographed	photograph	VBD	O
using	use	VBG	O
a	a	DT	O
Nikon	Nikon	NNP	O
Microphot	Microphot	NNP	O
microscope	microscope	NN	O
.	.	.	O

All	all	PDT	O
the	the	DT	O
procedures	procedure	NNS	O
were	be	VBD	O
carried	carry	VBN	O
out	out	RP	O
at	at	IN	O
room	room	NN	O
temperature	temperature	NN	O
unless	unless	IN	O
stated	state	VBN	O
otherwise	otherwise	RB	O
.	.	.	O

The	the	DT	O
GraphPad	GraphPad	NNP	O
Prism	Prism	NNP	O
software	software	NN	O
was	be	VBD	O
used	use	VBN	O
to	to	TO	O
perform	perform	VB	O
some	some	DT	O
of	of	IN	O
the	the	DT	O
statistical	statistical	JJ	O
analyses	analysis	NNS	O
.	.	.	O

For	for	IN	O
statistical	statistical	JJ	O
analysis	analysis	NN	O
of	of	IN	O
the	the	DT	O
toxicity	toxicity	NN	O
parameters	parameter	NNS	O
,	,	,	O
a	a	DT	O
two	two	CD	O
-	-	HYPH	O
tailed	tail	VBN	O
Fisherâs	fisherâs	CD	O
test	test	NN	O
was	be	VBD	O
used	use	VBN	O
and	and	CC	O
p	p	CD	O
values	value	NNS	O
below	below	IN	O
0.05	0.05	CD	O
were	be	VBD	O
considered	consider	VBN	O
significant	significant	JJ	O
.	.	.	O

Thiourea	Thiourea	NNP	O
derivatives	derivative	VBZ	O
3	3	CD	O
and	and	CC	O
4	4	CD	O
were	be	VBD	O
prepared	prepare	VBN	O
starting	start	VBG	O
from	from	IN	O
the	the	DT	O
amino	amino	JJ	O
analogue	analogue	NN	O
of	of	IN	O
metronidazole	metronidazole	NNP	O
1	1	CD	O
which	which	WDT	O
was	be	VBD	O
converted	convert	VBN	O
to	to	IN	O
isothiocyanate	isothiocyanate	NN	O
2	2	CD	O
using	use	VBG	O
thiophosgene	thiophosgene	JJ	O
under	under	IN	O
basic	basic	JJ	O
conditions	condition	NNS	O
.	.	.	O

Reaction	reaction	NN	O
either	either	CC	O
with	with	IN	O
4-aniline	4-aniline	CD	O
or	or	CC	O
4-phenol	4-phenol	CD	O
in	in	IN	O
acetonitrile	acetonitrile	NNP	O
led	lead	VBD	O
to	to	IN	O
the	the	DT	O
thiourea	thiourea	NNP	O
-	-	HYPH	O
derivatives	derivative	NNS	O
which	which	WDT	O
were	be	VBD	O
then	then	RB	O
sulphamoylated	sulphamoylate	VBN	O
with	with	IN	O
sulphamoyl	sulphamoyl	NNP	O
chloride	chloride	NN	O
to	to	TO	O
give	give	VB	O
,	,	,	O
respectively	respectively	RB	O
,	,	,	O
sulphamide	sulphamide	VB	O
3	3	CD	O
and	and	CC	O
sulphamate	sulphamate	VB	O
4	4	CD	B
,	,	,	B
.	.	.	O

Synthesis	synthesis	NN	O
of	of	IN	O
thioureas	thiourea	NNS	O
3	3	CD	O
and	and	CC	O
4	4	CD	O
.	.	.	O

Reagents	reagent	NNS	O
and	and	CC	O
conditions	condition	NNS	O
:	:	:	O
thiophosgene	thiophosgene	JJ	O
,	,	,	O
NaOH	NaOH	NNP	O
,	,	,	O
CHCl3	CHCl3	NNP	O
,	,	,	O
0âÂ	0ââ	CD	O
°	°	,	O
C	C	NNP	O
-	-	HYPH	O
rt	rt	NNP	O
;	;	:	O
4-aniline	4-aniline	CD	O
,	,	,	O
CH3CN	CH3CN	NNP	O
,	,	,	O
rt	rt	NNP	O
;	;	:	O
NH2SO2Cl	NH2SO2Cl	NNP	O
,	,	,	O
DMA	DMA	NNP	O
,	,	,	O
rt	rt	NNP	O
;	;	:	O
4-phenol	4-phenol	CD	O
,	,	,	O
CH3CN	CH3CN	NNP	O
,	,	,	O
rt	rt	NNP	O
;	;	:	O
NH2SO2Cl	NH2SO2Cl	NNP	O
,	,	,	O
DMA	DMA	NNP	O
,	,	,	O
rt	rt	NNP	O
.	.	.	O

Compound	Compound	NNP	O
10	10	CD	O
was	be	VBD	O
prepared	prepare	VBN	O
in	in	IN	O
a	a	DT	O
five	five	CD	O
-	-	HYPH	O
step	step	NN	O
synthesis	synthesis	NN	O
starting	start	VBG	O
from	from	IN	O
metronidazole	metronidazole	NNP	O
5	5	CD	O
.	.	.	O

Mesylation	mesylation	NN	O
of	of	IN	O
5	5	CD	O
using	use	VBG	O
methane	methane	NN	O
sulphonyl	sulphonyl	NN	O
chloride	chloride	NN	O
under	under	IN	O
basic	basic	JJ	O
conditions	condition	NNS	O
led	lead	VBN	O
to	to	TO	O
compound	compound	VB	O
6	6	CD	O
.	.	.	O

Reactions	reaction	NNS	O
with	with	IN	O
potassium	potassium	NN	O
thioacetate	thioacetate	NN	O
followed	follow	VBN	O
by	by	IN	O
oxidation	oxidation	NN	O
and	and	CC	O
treatment	treatment	NN	O
with	with	IN	O
phosgene	phosgene	NN	O
allowed	allow	VBD	O
the	the	DT	O
formation	formation	NN	O
of	of	IN	O
sulphonyl	sulphonyl	NN	O
chloride	chloride	NN	O
9	9	CD	O
.	.	.	O

Finally	finally	RB	O
,	,	,	O
compound	compound	NN	O
10	10	CD	O
was	be	VBD	O
obtained	obtain	VBN	O
by	by	IN	O
treatment	treatment	NN	O
with	with	IN	O
a	a	DT	O
solution	solution	NN	O
ammonia	ammonia	NN	O
in	in	IN	O
1,4-dioxane	1,4-dioxane	NN	O
at	at	IN	O
room	room	NN	O
temperature	temperature	NN	B
.	.	.	O

Synthesis	synthesis	NN	O
of	of	IN	O
sulphonamide	sulphonamide	JJ	O
10	10	CD	O
.	.	.	O

Reagents	reagent	NNS	O
and	and	CC	O
conditions	condition	NNS	O
:	:	:	O
CH3SO2Cl	CH3SO2Cl	NNP	O
,	,	,	O
NEt3	NEt3	NNP	O
,	,	,	O
DMAP	DMAP	NNP	O
,	,	,	O
DCM	DCM	NNP	O
,	,	,	O
0âÂ	0ââ	CD	O
°	°	,	O
C	C	NNP	O
â	â	NNP	O
rt	rt	NNP	O
;	;	:	O
KSAc	KSAc	NNP	O
,	,	,	O
DMF	DMF	NNP	O
,	,	,	O
rt	rt	NNP	O
;	;	:	O
35	35	CD	O
%	%	NN	O
H2O2-CH3COOH	H2O2-CH3COOH	NNPS	O
,	,	,	O
rt	rt	NNP	O
;	;	:	O
phosgene	phosgene	NN	O
,	,	,	O
cat	cat	NN	O
.	.	.	O

dry	dry	JJ	O
DMF	DMF	NNP	O
,	,	,	O
dry	dry	JJ	O
DCM	DCM	NNP	O
,	,	,	O
rt	rt	NNP	O
,	,	,	O
NH3	NH3	NNP	O
in	in	IN	O
1,4	1,4	CD	O
dioxane	dioxane	NN	O
,	,	,	O
benzene	benzene	NNP	O
,	,	,	O
rt	rt	NNP	O
.	.	.	O

All	all	DT	O
compounds	compound	NNS	O
reported	report	VBN	O
here	here	RB	O
were	be	VBD	O
assayed	assay	VBN	O
as	as	IN	O
inhibitors	inhibitor	NNS	O
of	of	IN	O
three	three	CD	O
physiologically	physiologically	RB	O
relevant	relevant	JJ	O
CA	CA	NNP	O
isoforms	isoform	NNS	O
,	,	,	O
the	the	DT	O
cytosolic	cytosolic	NN	O
hCA	hCA	NNP	O
I	-PRON-	PRP	O
and	and	CC	O
II	II	NNP	O
and	and	CC	O
the	the	DT	O
transmembrane	transmembrane	NN	O
,	,	,	O
tumour	tumour	NN	O
-	-	HYPH	O
associated	associate	VBN	O
hCA	hca	CD	O
IX	IX	NNP	O
using	use	VBG	O
the	the	DT	O
CO2	CO2	NNP	O
hydrase	hydrase	NN	O
assay	assay	NN	B
.	.	.	O

The	the	DT	O
clinically	clinically	RB	O
employed	employ	VBN	O
sulphonamide	sulphonamide	RB	O
,	,	,	O
acetazolamide	acetazolamide	RB	O
,	,	,	O
has	have	VBZ	O
been	be	VBN	O
used	use	VBN	O
as	as	IN	O
a	a	DT	O
standard	standard	NN	O
in	in	IN	O
these	these	DT	O
measurements	measurement	NNS	O
.	.	.	O

Inhibition	inhibition	NN	O
data	datum	NNS	O
of	of	IN	O
compounds	compound	NNS	O
3	3	CD	O
,	,	,	O
4	4	CD	O
and	and	CC	O
10	10	CD	O
against	against	IN	O
hCA	hCA	NNP	O
I	-PRON-	PRP	O
,	,	,	O
hCA	hCA	VBD	O
II	II	NNP	O
and	and	CC	O
hCA	hCA	NNP	O
IX	IX	NNP	O
using	use	VBG	O
a	a	DT	O
stopped	stop	VBN	O
flow	flow	NN	O
CO2	CO2	NNP	O
hydrase	hydrase	NN	O
assay	assay	NN	O
.	.	.	O

Average	average	JJ	O
from	from	IN	O
three	three	CD	O
different	different	JJ	O
assays	assay	NNS	O
,	,	,	O
by	by	IN	O
a	a	DT	O
stopped	stop	VBN	O
flow	flow	NN	O
technique	technique	NN	O
errors	error	NNS	O
were	be	VBD	O
in	in	IN	O
the	the	DT	O
range	range	NN	O
of	of	IN	O
Â±	Â±	NNP	O
5â10	5â10	CD	O
%	%	NN	O
of	of	IN	O
the	the	DT	O
reported	report	VBN	O
values	value	NNS	O
.	.	.	O

Compound	Compound	NNP	O
10	10	CD	O
showed	show	VBD	O
very	very	RB	O
weak	weak	JJ	O
inhibition	inhibition	NN	O
potency	potency	NN	O
against	against	IN	O
the	the	DT	O
abundant	abundant	JJ	O
cytosolic	cytosolic	NN	O
hCA	hCA	NNP	O
I	-PRON-	PRP	O
with	with	IN	O
a	a	DT	O
KIvalue	KIvalue	NNP	O
of	of	IN	O
6428ânM.	6428ânm.	CD	O
The	the	DT	O
thiourea	thiourea	NNP	O
derivatives	derivative	VBZ	O
3	3	CD	O
and	and	CC	O
4	4	CD	O
demonstrated	demonstrate	VBD	O
sub	sub	JJ	O
-	-	JJ	O
micromolar	micromolar	JJ	O
inhibition	inhibition	NN	O
potency	potency	NN	O
against	against	IN	O
all	all	DT	O
CA	CA	NNP	O
isoforms	isoform	NNS	O
.	.	.	O

Compound	compound	NN	O
4	4	CD	O
showed	show	VBD	O
the	the	DT	O
most	most	RBS	O
efficient	efficient	JJ	O
binding	bind	VBG	O
to	to	TO	O
hCA	hca	XX	O
II	II	NNP	O
KI=	KI=	NNP	O
58.6ânM	58.6ânm	CD	O
with	with	IN	O
a	a	DT	O
selectivity	selectivity	NN	O
ratio	ratio	NN	O
of	of	IN	O
0.09	0.09	CD	O
for	for	IN	O
inhibiting	inhibit	VBG	O
hCA	hca	CD	O
II	II	NNP	O
over	over	IN	O
hCA	hCA	NNP	O
IX	IX	NNP	O
,	,	,	O
explained	explain	VBN	O
by	by	IN	O
the	the	DT	O
influence	influence	NN	O
of	of	IN	O
the	the	DT	O
substitution	substitution	NN	O
on	on	IN	O
the	the	DT	O
benzene	benzene	NN	O
ring	ring	NN	O
.	.	.	O

Compound	Compound	NNP	O
10	10	CD	O
,	,	,	O
the	the	DT	O
sulphonamide	sulphonamide	JJ	O
derivative	derivative	NN	O
of	of	IN	O
the	the	DT	O
sulphamide	sulphamide	NN	O
and	and	CC	O
sulphamate	sulphamate	NN	O
analogues	analogue	NNS	O
previously	previously	RB	O
reported	report	VBN	O
and	and	CC	O
biologically	biologically	RB	O
evaluated	evaluate	VBN	O
by	by	IN	O
our	-PRON-	PRP$	O
group	group	NN	B
,	,	,	O
showed	show	VBD	O
moderate	moderate	JJ	O
binding	bind	VBG	O
efficacy	efficacy	NN	O
towards	towards	IN	O
hCA	hca	CD	O
II	II	NNP	O
KI=	ki=	ADD	O
199.2ânM	199.2ânm	CD	O
and	and	CC	O
hCA	hCA	NNP	O
IX	IX	NNP	O
KI=	ki=	ADD	O
147.3ânM	147.3ânm	CD	O
.	.	.	O

The	the	DT	O
better	well	RBR	O
binding	bind	VBG	O
efficacy	efficacy	NN	O
of	of	IN	O
sulphonamide	sulphonamide	NN	O
10	10	CD	O
compared	compare	VBN	O
to	to	IN	O
the	the	DT	O
sulphamide	sulphamide	NN	O
and	and	CC	O
sulphamate	sulphamate	VB	O
compounds	compound	NNS	O
might	may	MD	O
be	be	VB	O
explained	explain	VBN	O
by	by	IN	O
higher	high	JJR	O
stability	stability	NN	O
under	under	IN	O
acidic	acidic	JJ	O
conditions	condition	NNS	O
,	,	,	O
i.e.	i.e.	FW	O
sulphonamideâ>âsulphamideâ>âsulphamate	sulphonamideâ>âsulphamideâ>âsulphamate	FW	O
.	.	.	O

The	the	DT	O
lethal	lethal	JJ	O
effects	effect	NNS	O
of	of	IN	O
all	all	DT	O
three	three	CD	O
inhibitor	inhibitor	NN	O
compounds	compound	NNS	O
were	be	VBD	O
concentration	concentration	NN	O
dependent	dependent	JJ	O
on	on	IN	O
the	the	DT	O
developing	develop	VBG	O
zebrafish	zebrafish	JJ	O
embryos	embryo	NNS	O
that	that	WDT	O
were	be	VBD	O
exposed	expose	VBN	O
to	to	IN	O
the	the	DT	O
inhibitor	inhibitor	NN	O
for	for	IN	O
5	5	CD	O
d	d	NN	O
.	.	.	O

None	none	NN	O
of	of	IN	O
the	the	DT	O
three	three	CD	O
inhibitors	inhibitor	NNS	O
exhibited	exhibit	VBD	O
any	any	DT	O
significant	significant	JJ	O
mortality	mortality	NN	O
in	in	IN	O
up	up	IN	O
to	to	TO	O
1.5âmM	1.5âmm	CD	O
concentration	concentration	NN	O
at	at	IN	O
the	the	DT	O
end	end	NN	O
of	of	IN	O
5	5	CD	O
d	d	NN	O
of	of	IN	O
exposure	exposure	NN	O
to	to	IN	O
the	the	DT	O
inhibitors	inhibitor	NNS	O
.	.	.	O

Significant	significant	JJ	O
mortality	mortality	NN	O
of	of	IN	O
zebrafish	zebrafish	NNP	O
larvae	larvae	NNP	O
emerged	emerge	VBD	O
at	at	IN	O
higher	high	JJR	O
concentrations	concentration	NNS	O
>	>	XX	O
2âmM	2âmm	CD	O
,	,	,	O
and	and	CC	O
the	the	DT	O
LC50	LC50	NNP	O
values	value	NNS	O
at	at	IN	O
the	the	DT	O
end	end	NN	O
of	of	IN	O
five	five	CD	O
days	day	NNS	O
were	be	VBD	O
3âmM	3âmm	CD	O
for	for	IN	O
3	3	CD	O
and	and	CC	O
2.6âmM	2.6âmm	CD	O
for	for	IN	O
4	4	CD	O
and	and	CC	O
10	10	CD	O
.	.	.	O

The	the	DT	O
half	half	JJ	O
maximal	maximal	JJ	O
lethal	lethal	JJ	O
concentrations	concentration	NNS	O
of	of	IN	O
the	the	DT	O
inhibitors	inhibitor	NNS	O
were	be	VBD	O
higher	high	JJR	O
compared	compare	VBN	O
to	to	IN	O
any	any	DT	O
toxicity	toxicity	NN	O
and	and	CC	O
safety	safety	NN	O
assessment	assessment	NN	O
studies	study	NNS	O
that	that	IN	O
we	-PRON-	PRP	O
have	have	VBP	O
performed	perform	VBN	O
earlier	early	JJR	B
,	,	,	O
suggesting	suggest	VBG	O
that	that	IN	O
these	these	DT	O
compounds	compound	NNS	O
can	can	MD	O
be	be	VB	O
further	further	RB	O
developed	develop	VBN	O
as	as	IN	O
inhibitors	inhibitor	NNS	O
of	of	IN	O
human	human	JJ	O
CA	CA	NNP	O
I	I	NNP	O
,	,	,	O
CA	CA	NNP	O
II	II	NNP	O
and	and	CC	O
CA	CA	NNP	O
IX	IX	NNP	O
.	.	.	O

The	the	DT	O
LC50	LC50	NNP	O
values	value	NNS	O
of	of	IN	O
the	the	DT	O
tested	test	VBN	O
CA	CA	NNP	O
inhibitor	inhibitor	NN	O
compounds	compound	NNS	O
.	.	.	O

The	the	DT	O
LC50	LC50	NNP	O
doses	dose	VBZ	O
for	for	IN	O
the	the	DT	O
inhibitors	inhibitor	NNS	O
were	be	VBD	O
determined	determine	VBN	O
based	base	VBN	O
on	on	IN	O
the	the	DT	O
50	50	CD	O
%	%	NN	O
mortality	mortality	NN	O
of	of	IN	O
the	the	DT	O
larvae	larvae	NN	O
at	at	IN	O
the	the	DT	O
end	end	NN	O
of	of	IN	O
5	5	CD	O
d	d	NNS	O
after	after	IN	O
the	the	DT	O
exposure	exposure	NN	O
of	of	IN	O
embryos	embryo	NNS	O
to	to	IN	O
different	different	JJ	O
concentrations	concentration	NNS	O
of	of	IN	O
inhibitors	inhibitor	NNS	O
:	:	:	O
compound	compound	NNP	O
3	3	CD	O
,	,	,	O
4	4	CD	O
and	and	CC	O
10	10	CD	O
.	.	.	O

The	the	DT	O
LC50	LC50	NNP	O
doses	dose	NNS	O
were	be	VBD	O
determined	determine	VBN	O
after	after	IN	O
three	three	CD	O
independent	independent	JJ	O
experiments	experiment	NNS	O
with	with	IN	O
similar	similar	JJ	O
experimental	experimental	JJ	O
conditions	condition	NNS	O
for	for	IN	O
each	each	DT	O
compound	compound	NN	O
Nâ=â90	nâ=â90	LS	O
.	.	.	O

To	to	TO	O
assess	assess	VB	O
toxic	toxic	JJ	O
effects	effect	NNS	O
of	of	IN	O
the	the	DT	O
inhibitors	inhibitor	NNS	O
on	on	IN	O
the	the	DT	O
developing	develop	VBG	O
zebrafish	zebrafish	JJ	O
larvae	larvae	NNP	O
we	-PRON-	PRP	O
analysed	analyse	VBD	O
eight	eight	CD	O
observable	observable	JJ	O
phenotypic	phenotypic	NN	O
parameters	parameter	NNS	O
namely	namely	RB	O
:	:	:	O
hatching	hatching	NN	O
,	,	,	O
heartbeat	heartbeat	NN	O
,	,	,	O
yolk	yolk	NNP	O
sack	sack	NN	O
utilisation	utilisation	NN	O
,	,	,	O
movement	movement	NN	O
pattern	pattern	NN	O
,	,	,	O
body	body	NN	O
shape	shape	NN	O
,	,	,	O
swim	swim	VB	O
bladder	bladder	NN	O
development	development	NN	O
,	,	,	O
mortality	mortality	NN	O
and	and	CC	O
oedema	oedema	NN	O
.	.	.	O

The	the	DT	O
parameters	parameter	NNS	O
were	be	VBD	O
monitored	monitor	VBN	O
using	use	VBG	O
a	a	DT	O
stereo	stereo	NN	O
microscope	microscope	NN	O
and	and	CC	O
observations	observation	NNS	O
were	be	VBD	O
recorded	record	VBN	O
for	for	IN	O
each	each	DT	O
group	group	NN	O
in	in	IN	O
comparison	comparison	NN	O
with	with	IN	O
control	control	NN	O
embryos	embryo	NNS	O
that	that	WDT	O
were	be	VBD	O
not	not	RB	O
treated	treat	VBN	O
with	with	IN	O
any	any	DT	O
of	of	IN	O
the	the	DT	O
compounds	compound	NNS	O
or	or	CC	O
treated	treat	VBN	O
with	with	IN	O
1	1	CD	O
%	%	NN	O
DMSO	DMSO	NNS	O
.	.	.	O

The	the	DT	O
images	image	NNS	O
in	in	IN	O
Figure	Figure	NNP	O
2	2	CD	O
show	show	VBP	O
the	the	DT	O
representative	representative	JJ	O
larvae	larvae	NNP	O
exposed	expose	VBN	O
to	to	IN	O
the	the	DT	O
compounds	compound	NNS	O
with	with	IN	O
concentrations	concentration	NNS	O
ranging	range	VBG	O
from	from	IN	O
75âÂµM	75ââµm	CD	O
to	to	IN	O
500âÂµM	500ââµm	CD	O
as	as	IN	O
compared	compare	VBN	O
to	to	IN	O
the	the	DT	O
control	control	NN	O
group	group	NN	O
larvae	larvae	NNP	O
.	.	.	O

The	the	DT	O
microscopic	microscopic	JJ	O
examination	examination	NN	O
did	do	VBD	O
not	not	RB	O
show	show	VB	O
any	any	DT	O
of	of	IN	O
the	the	DT	O
observable	observable	JJ	O
changes	change	NNS	O
in	in	IN	O
the	the	DT	O
developing	develop	VBG	O
zebrafish	zebrafish	JJ	O
embryos	embryo	NNS	O
at	at	IN	O
these	these	DT	O
concentrations	concentration	NNS	O
and	and	CC	O
the	the	DT	O
embryos	embryo	NNS	O
showed	show	VBD	O
normal	normal	JJ	O
phenotypes	phenotype	NNS	O
throughout	throughout	IN	O
the	the	DT	O
period	period	NN	O
of	of	IN	O
embryonic	embryonic	JJ	O
development	development	NN	O
from	from	IN	O
2	2	CD	O
to	to	IN	O
5	5	CD	O
dpf	dpf	NN	O
.	.	.	O

The	the	DT	O
images	image	NNS	O
of	of	IN	O
zebrafish	zebrafish	NNP	O
larvae	larvae	NNP	O
in	in	IN	O
control	control	NN	O
and	and	CC	O
inhibitor	inhibitor	NN	O
treated	treat	VBN	O
groups	group	NNS	O
.	.	.	O

Representative	representative	JJ	O
images	image	NNS	O
of	of	IN	O
2â5	2â5	CD	O
dpf	dpf	NNP	O
zebrafish	zebrafish	NNP	O
larvae	larvae	NNP	O
exposed	expose	VBN	O
to	to	IN	O
different	different	JJ	O
concentrations	concentration	NNS	O
75	75	CD	O
,	,	,	O
250	250	CD	O
and	and	CC	O
500âÎ¼M	500âî¼m	CD	O
of	of	IN	O
compound	compound	NNP	O
3	3	CD	O
,	,	,	O
4	4	CD	O
and	and	CC	O
10	10	CD	O
.	.	.	O

The	the	DT	O
images	image	NNS	O
of	of	IN	O
control	control	NN	O
group	group	NN	O
and	and	CC	O
1	1	CD	O
%	%	NN	O
DMSO	DMSO	NNP	O
treated	treat	VBD	O
zebrafish	zebrafish	NNP	O
larvae	larvae	NNP	O
show	show	VBP	O
normal	normal	JJ	O
development	development	NN	O
nâ=â60	nâ=â60	NNP	O
.	.	.	O

We	-PRON-	PRP	O
further	further	RB	O
assessed	assess	VBD	O
the	the	DT	O
toxicity	toxicity	NN	O
of	of	IN	O
compounds	compound	NNS	O
3	3	CD	O
,	,	,	O
4	4	CD	O
and	and	CC	O
10	10	CD	O
compounds	compound	NNS	O
in	in	IN	O
zebrafish	zebrafish	NNP	O
larvae	larvae	NNP	O
across	across	IN	O
the	the	DT	O
concentration	concentration	NN	O
range	range	NN	O
12âÂµMâ3âmM.	12ââµmâ3âmm.	CD	O
Figure	figure	NN	O
3	3	CD	O
presents	present	VBZ	O
plots	plot	NNS	O
of	of	IN	O
dose	dose	VB	O
-	-	HYPH	O
dependent	dependent	JJ	O
effects	effect	NNS	O
of	of	IN	O
inhibitors	inhibitor	NNS	O
on	on	IN	O
different	different	JJ	O
parameters	parameter	NNS	O
in	in	IN	O
treated	treat	VBN	O
larvae	larvae	NNP	O
.	.	.	O

The	the	DT	O
results	result	NNS	O
indicated	indicate	VBD	O
that	that	IN	O
none	none	NN	O
of	of	IN	O
the	the	DT	O
inhibitors	inhibitor	NNS	O
show	show	VBP	O
significant	significant	JJ	O
toxic	toxic	JJ	O
effects	effect	NNS	O
at	at	IN	O
submillimolar	submillimolar	JJ	O
range	range	NN	O
.	.	.	O

Previous	previous	JJ	O
toxicity	toxicity	NN	O
studies	study	NNS	O
on	on	IN	O
hCA	hCA	NNP	O
IX	IX	NNP	O
and	and	CC	O
mycobacterial	mycobacterial	NN	O
Î²-CA	î²-ca	NN	O
inhibitors	inhibitor	NNS	O
showed	show	VBD	O
significant	significant	JJ	O
effects	effect	NNS	O
on	on	IN	O
larval	larval	NN	O
mortality	mortality	NN	O
and	and	CC	O
observable	observable	JJ	O
phenotypic	phenotypic	JJ	O
parameters	parameter	NNS	O
in	in	IN	O
the	the	DT	O
concentration	concentration	NN	O
range	range	NN	O
of	of	IN	O
50â300âÂµM	50â300ââµm	CD	B
,	,	,	B
.	.	.	O

Therefore	therefore	RB	O
,	,	,	O
our	-PRON-	PRP$	O
present	present	JJ	O
results	result	NNS	O
show	show	VBP	O
that	that	IN	O
3	3	CD	O
,	,	,	O
4	4	CD	O
and	and	CC	O
10	10	CD	O
are	be	VBP	O
less	less	RBR	O
toxic	toxic	JJ	O
in	in	IN	O
the	the	DT	O
zebrafish	zebrafish	NNP	O
larval	larval	NN	O
model	model	NN	O
.	.	.	O

The	the	DT	O
effect	effect	NN	O
of	of	IN	O
compounds	compound	NNS	O
3	3	CD	O
,	,	,	O
4	4	CD	O
and	and	CC	O
10	10	CD	O
CA	CA	NNP	O
inhibitors	inhibitor	NNS	O
on	on	IN	O
the	the	DT	O
phenotypic	phenotypic	JJ	O
parameters	parameter	NNS	O
of	of	IN	O
the	the	DT	O
5	5	CD	O
dpf	dpf	NNP	O
zebrafish	zebrafish	NNP	O
larvae	larvae	NNP	O
.	.	.	O

The	the	DT	O
plot	plot	NN	O
graphs	graphs	NN	O
of	of	IN	O
different	different	JJ	O
phenotypic	phenotypic	JJ	O
abnormalities	abnormality	NNS	O
in	in	IN	O
hatching	hatching	NN	O
,	,	,	O
oedema	oedema	NN	O
,	,	,	O
heartbeat	heartbeat	NN	O
body	body	NN	O
shape	shape	NN	O
and	and	CC	O
yolk	yolk	NN	O
sac	sac	NN	O
utilisation	utilisation	NN	O
.	.	.	O

For	for	IN	O
each	each	DT	O
concentration	concentration	NN	O
,	,	,	O
nâ=â90	nâ=â90	ADD	O
.	.	.	O

*	*	NFP	O
pâ<â0.05	pâ<â0.05	NN	O
by	by	IN	O
two	two	CD	O
-	-	HYPH	O
tailed	tail	VBN	O
Fisherâs	fisherâs	CD	O
test	test	NN	O
.	.	.	O

The	the	DT	O
effects	effect	NNS	O
of	of	IN	O
different	different	JJ	O
concentrations	concentration	NNS	O
of	of	IN	O
CA	CA	NNP	O
inhibitors	inhibitor	NNS	O
on	on	IN	O
histology	histology	NN	O
were	be	VBD	O
studied	study	VBN	O
by	by	IN	O
analysing	analyse	VBG	O
the	the	DT	O
sections	section	NNS	O
of	of	IN	O
5	5	CD	O
dpf	dpf	NNP	O
zebrafish	zebrafish	NNP	O
larvae	larvae	NNP	O
stained	stain	VBN	O
with	with	IN	O
haematoxylin	haematoxylin	NNP	O
and	and	CC	O
eosin	eosin	NN	O
.	.	.	O

The	the	DT	O
stained	stained	JJ	O
sagittal	sagittal	JJ	O
sections	section	NNS	O
of	of	IN	O
both	both	CC	O
the	the	DT	O
inhibitor	inhibitor	NN	O
treated	treat	VBN	O
and	and	CC	O
control	control	NN	O
larvae	larva	NNS	O
were	be	VBD	O
compared	compare	VBN	O
by	by	IN	O
light	light	NN	O
microscopy	microscopy	NN	O
.	.	.	O

Representative	representative	JJ	O
images	image	NNS	O
of	of	IN	O
zebrafish	zebrafish	JJ	O
larval	larval	NN	O
sections	section	NNS	O
are	be	VBP	O
shown	show	VBN	O
in	in	IN	O
Figure	Figure	NNP	O
4	4	CD	O
.	.	.	O

The	the	DT	O
histological	histological	JJ	O
examination	examination	NN	O
revealed	reveal	VBD	O
no	no	DT	O
damage	damage	NN	O
to	to	IN	O
the	the	DT	O
tissues	tissue	NNS	O
of	of	IN	O
the	the	DT	O
developing	develop	VBG	O
zebrafish	zebrafish	JJ	O
larvae	larvae	NN	O
.	.	.	O

Even	even	RB	O
high	high	JJ	O
concentrations	concentration	NNS	O
up	up	IN	O
to	to	IN	O
2âmM	2âmm	CD	O
showed	show	VBD	O
no	no	DT	O
apparent	apparent	JJ	O
damage	damage	NN	O
to	to	IN	O
the	the	DT	O
internal	internal	JJ	O
tissues	tissue	NNS	O
,	,	,	O
suggesting	suggest	VBG	O
that	that	IN	O
these	these	DT	O
compounds	compound	NNS	O
are	be	VBP	O
safe	safe	JJ	O
and	and	CC	O
can	can	MD	O
be	be	VB	O
further	further	RB	O
developed	develop	VBN	O
as	as	IN	O
CA	CA	NNP	O
-	-	HYPH	O
specific	specific	JJ	O
inhibitors	inhibitor	NNS	O
for	for	IN	O
clinical	clinical	JJ	O
use	use	NN	O
.	.	.	O

Histochemical	histochemical	JJ	O
analyses	analysis	NNS	O
of	of	IN	O
zebrafish	zebrafish	JJ	O
larvae	larvae	NNP	O
.	.	.	O

Representative	representative	JJ	O
sagittal	sagittal	JJ	O
sections	section	NNS	O
of	of	IN	O
an	an	DT	O
untreated	untreated	JJ	O
zebrafish	zebrafish	JJ	O
larva	larva	NN	O
or	or	CC	O
larva	larva	NNS	O
treated	treat	VBN	O
with	with	IN	O
500âÎ¼M	500âî¼m	CD	O
of	of	IN	O
compound	compound	NN	O
3	3	CD	O
,	,	,	O
4	4	CD	O
or	or	CC	O
10	10	CD	O
.	.	.	O

The	the	DT	O
images	image	NNS	O
presented	present	VBN	O
here	here	RB	O
are	be	VBP	O
selected	select	VBN	O
from	from	IN	O
three	three	CD	O
independent	independent	JJ	O
groups	group	NNS	O
of	of	IN	O
experiments	experiment	NNS	O
.	.	.	O

During	during	IN	O
development	development	NN	O
,	,	,	O
zebrafish	zebrafish	NNP	O
embryos	embryo	NNS	O
are	be	VBP	O
easily	easily	RB	O
affected	affect	VBN	O
by	by	IN	O
chemical	chemical	JJ	O
compounds	compound	NNS	O
compared	compare	VBN	O
to	to	TO	O
adult	adult	VB	O
zebrafish	zebrafish	NNP	O
or	or	CC	O
other	other	JJ	O
animal	animal	NN	O
or	or	CC	O
cell	cell	NN	O
models	model	NNS	O
,	,	,	O
and	and	CC	O
therefore	therefore	RB	O
are	be	VBP	O
suitable	suitable	JJ	O
for	for	IN	O
assessing	assess	VBG	O
the	the	DT	O
subtle	subtle	JJ	O
toxic	toxic	JJ	O
effects	effect	NNS	O
of	of	IN	O
the	the	DT	O
chemicals	chemical	NNS	B
,	,	,	B
.	.	.	O

To	to	TO	O
assess	assess	VB	O
the	the	DT	O
subtle	subtle	JJ	O
toxic	toxic	JJ	O
effects	effect	NNS	O
of	of	IN	O
the	the	DT	O
inhibitors	inhibitor	NNS	O
,	,	,	O
the	the	DT	O
swim	swim	NN	O
pattern	pattern	NN	O
of	of	IN	O
the	the	DT	O
larvae	larvae	NN	O
was	be	VBD	O
examined	examine	VBN	O
under	under	IN	O
the	the	DT	O
microscope	microscope	NN	O
during	during	IN	O
treatment	treatment	NN	O
with	with	IN	O
the	the	DT	O
CA	CA	NNP	O
inhibitors	inhibitor	NNS	O
.	.	.	O

The	the	DT	O
swim	swim	NN	O
pattern	pattern	NN	O
analysis	analysis	NN	O
showed	show	VBD	O
no	no	DT	O
abnormal	abnormal	JJ	O
or	or	CC	O
ataxic	ataxic	JJ	O
movement	movement	NN	O
pattern	pattern	NN	O
in	in	IN	O
the	the	DT	O
larvae	larvae	NNP	O
exposed	expose	VBN	O
to	to	IN	O
the	the	DT	O
inhibitors	inhibitor	NNS	O
,	,	,	O
up	up	RB	O
to	to	TO	O
2âmM	2âmm	CD	O
concentration	concentration	NN	O
.	.	.	O

However	however	RB	O
,	,	,	O
a	a	DT	O
detailed	detailed	JJ	O
analysis	analysis	NN	O
of	of	IN	O
the	the	DT	O
videos	video	NNS	O
at	at	IN	O
the	the	DT	O
end	end	NN	O
of	of	IN	O
5âd	5âd	CD	O
of	of	IN	O
inhibitor	inhibitor	NN	O
exposure	exposure	NN	O
showed	show	VBD	O
that	that	IN	O
the	the	DT	O
larvae	larvae	NN	O
of	of	IN	O
the	the	DT	O
inhibitor	inhibitor	NN	O
treated	treat	VBN	O
groups	group	NNS	O
125âÂµM	125ââµm	CD	O
were	be	VBD	O
not	not	RB	O
as	as	RB	O
active	active	JJ	O
and	and	CC	O
tended	tend	VBD	O
to	to	TO	O
remain	remain	VB	O
at	at	IN	O
the	the	DT	O
sides	side	NNS	O
of	of	IN	O
petri	petri	JJ	O
dish	dish	NN	O
compared	compare	VBN	O
to	to	IN	O
the	the	DT	O
control	control	NN	O
group	group	NN	O
larvae	larvae	NNP	O
.	.	.	O

The	the	DT	O
results	result	NNS	O
of	of	IN	O
the	the	DT	O
current	current	JJ	O
study	study	NN	O
reveal	reveal	VBP	O
that	that	IN	O
the	the	DT	O
larvae	larvae	NNP	O
treated	treat	VBN	O
with	with	IN	O
3	3	CD	O
,	,	,	O
4	4	CD	O
and	and	CC	O
10	10	CD	O
become	become	VBP	O
slower	slow	JJR	O
while	while	IN	O
swimming	swim	VBG	O
as	as	IN	O
compared	compare	VBN	O
to	to	IN	O
the	the	DT	O
swim	swim	NN	O
pattern	pattern	NN	O
of	of	IN	O
the	the	DT	O
control	control	NN	O
group	group	NN	O
larvae	larvae	NNP	O
.	.	.	O

However	however	RB	O
,	,	,	O
swim	swim	VB	O
pattern	pattern	NN	O
of	of	IN	O
larvae	larvae	NNP	O
treated	treat	VBN	O
with	with	IN	O
3	3	CD	O
,	,	,	O
4	4	CD	O
and	and	CC	O
10	10	CD	O
was	be	VBD	O
unlike	unlike	IN	O
the	the	DT	O
larvae	larvae	NN	O
treated	treat	VBN	O
with	with	IN	O
nitroimidazole	nitroimidazole	NN	O
-	-	HYPH	O
based	base	VBN	O
inhibitors	inhibitor	NNS	O
DTP338	DTP338	NNP	O
and	and	CC	O
DTP348	DTP348	NNP	O
,	,	,	O
which	which	WDT	O
showed	show	VBD	O
ataxic	ataxic	NNP	O
movement	movement	NN	O
pattern	pattern	NN	O
due	due	IN	O
to	to	IN	O
neurotoxicity	neurotoxicity	NN	O
at	at	IN	O
a	a	DT	O
concentration	concentration	NN	O
as	as	RB	O
low	low	JJ	O
as	as	IN	O
100âÂµM	100ââµm	CD	B
.	.	.	O

Therefore	therefore	RB	O
,	,	,	O
these	these	DT	O
novel	novel	NN	O
thiourea	thiourea	NN	O
and	and	CC	O
sulphonamide	sulphonamide	VB	O
derivatives	derivative	NNS	O
can	can	MD	O
be	be	VB	O
considered	consider	VBN	O
safer	safe	JJR	O
for	for	IN	O
further	further	JJ	O
preclinical	preclinical	JJ	O
characterisation	characterisation	NN	O
and	and	CC	O
development	development	NN	O
as	as	IN	O
potential	potential	JJ	O
drugs	drug	NNS	O
.	.	.	O

In	in	IN	O
conclusion	conclusion	NN	O
,	,	,	O
we	-PRON-	PRP	O
have	have	VBP	O
designed	design	VBN	O
and	and	CC	O
synthesised	synthesise	VBN	O
thiourea	thiourea	NNP	O
and	and	CC	O
sulphonamide	sulphonamide	VB	O
derivative	derivative	JJ	O
compounds	compound	NNS	O
with	with	IN	O
the	the	DT	O
potential	potential	NN	O
to	to	TO	O
inhibit	inhibit	VB	O
human	human	JJ	O
CA	CA	NNP	O
I	I	NNP	O
,	,	,	O
CA	CA	NNP	O
II	II	NNP	O
and	and	CC	O
CA	CA	NNP	O
IX	IX	NNP	O
.	.	.	O

These	these	DT	O
proteins	protein	NNS	O
which	which	WDT	O
play	play	VBP	O
important	important	JJ	O
pathophysiological	pathophysiological	JJ	O
roles	role	NNS	O
in	in	IN	O
human	human	JJ	O
diseases	disease	NNS	O
,	,	,	O
such	such	JJ	O
as	as	IN	O
well	well	RB	O
-	-	HYPH	O
known	know	VBN	O
role	role	NN	O
of	of	IN	O
CA	CA	NNP	O
IX	IX	NNP	O
in	in	IN	O
the	the	DT	O
progression	progression	NN	O
of	of	IN	O
solid	solid	JJ	O
tumours	tumour	NNS	O
,	,	,	O
and	and	CC	O
those	those	DT	O
of	of	IN	O
CA	CA	NNP	O
I	I	NNP	O
and	and	CC	O
CA	CA	NNP	O
II	II	NNP	O
in	in	IN	O
retinal	retinal	JJ	O
and	and	CC	O
cerebral	cerebral	JJ	O
oedema	oedema	NNP	O
,	,	,	O
glaucoma	glaucoma	NN	O
,	,	,	O
epilepsy	epilepsy	NN	O
and	and	CC	O
altitude	altitude	NN	O
sickness	sickness	NN	O
.	.	.	O

The	the	DT	O
inhibition	inhibition	NN	O
kinetics	kinetic	NNS	O
of	of	IN	O
these	these	DT	O
inhibitors	inhibitor	NNS	O
were	be	VBD	O
studied	study	VBN	O
against	against	IN	O
recombinant	recombinant	JJ	O
human	human	JJ	O
hCA	hca	NN	O
I	-PRON-	PRP	O
,	,	,	O
hCA	hCA	VBD	O
II	II	NNP	O
and	and	CC	O
hCA	hCA	NNP	O
IX	IX	NNP	O
inÂ	inÂ	NNP	O
vitro	vitro	FW	O
.	.	.	O

Among	among	IN	O
these	these	DT	O
compounds	compound	NNS	O
,	,	,	O
4	4	CD	O
was	be	VBD	O
the	the	DT	O
most	most	RBS	O
efficient	efficient	JJ	O
against	against	IN	O
hCA	hca	CD	O
II	II	NNP	O
KI	KI	NNP	O
58.6ânM	58.6ânM	NNP	O
.	.	.	O

10	10	CD	O
inhibited	inhibit	VBN	O
human	human	JJ	O
CA	CA	NNP	O
IX	IX	NNP	O
with	with	IN	O
KI	KI	NNP	O
147.3ânM.	147.3ânm.	CD	O
The	the	DT	O
inhibition	inhibition	NN	O
properties	property	NNS	O
of	of	IN	O
these	these	DT	O
inhibitors	inhibitor	NNS	O
against	against	IN	O
the	the	DT	O
three	three	CD	O
hCA	hca	JJ	O
isoforms	isoform	NNS	O
prompted	prompt	VBD	O
us	-PRON-	PRP	O
to	to	TO	O
test	test	VB	O
these	these	DT	O
drugs	drug	NNS	O
further	far	RBR	O
for	for	IN	O
their	-PRON-	PRP$	O
safety	safety	NN	O
in	in	IN	O
a	a	DT	O
zebrafish	zebrafish	NNP	O
larval	larval	NN	O
model	model	NN	O
.	.	.	O

The	the	DT	O
toxicological	toxicological	JJ	O
evaluation	evaluation	NN	O
indicated	indicate	VBD	O
that	that	IN	O
these	these	DT	O
inhibitors	inhibitor	NNS	O
showed	show	VBD	O
no	no	DT	O
adverse	adverse	JJ	O
morphological	morphological	JJ	O
changes	change	NNS	O
nor	nor	CC	O
did	do	VBD	O
they	-PRON-	PRP	O
cause	cause	VB	O
abnormal	abnormal	JJ	O
swim	swim	NN	O
pattern	pattern	NN	O
at	at	IN	O
any	any	DT	O
sub	sub	JJ	O
-	-	JJ	O
millimolar	millimolar	JJ	O
concentration	concentration	NN	O
.	.	.	O

Taken	take	VBN	O
together	together	RB	O
,	,	,	O
the	the	DT	O
results	result	NNS	O
from	from	IN	O
both	both	CC	O
inÂ	inâ	JJ	O
vitro	vitro	FW	O
inhibition	inhibition	NN	O
studies	study	NNS	O
and	and	CC	O
toxicological	toxicological	JJ	O
evaluation	evaluation	NN	O
,	,	,	O
we	-PRON-	PRP	O
suggest	suggest	VBP	O
that	that	IN	O
these	these	DT	O
inhibitors	inhibitor	NNS	O
could	could	MD	O
be	be	VB	O
developed	develop	VBN	O
into	into	IN	O
potential	potential	JJ	O
drugs	drug	NNS	O
targeting	target	VBG	O
hCA	hca	XX	O
I	-PRON-	PRP	O
,	,	,	O
hCA	hCA	VBD	O
II	II	NNP	O
and	and	CC	O
hCA	hCA	NNP	O
IX	IX	NNP	O
with	with	IN	O
no	no	UH	O
,	,	,	O
or	or	CC	O
minimal	minimal	JJ	O
,	,	,	O
off	off	IN	O
-	-	HYPH	O
target	target	NN	O
effects	effect	NNS	O
.	.	.	O

